Optimal care pathway for people with melanoma
Statement of acknowledgement

We acknowledge the Traditional Owners of Country throughout Australia and their continuing connection to the land, sea and community. We pay our respects to them and their cultures and to Elders past, present and emerging.

This work is available from the Cancer Council website <www.cancer.org.au/OCP>.


ISBN: 978 1 76096 156 5


Enquiries about this publication can be sent to <optimalcare.pathways@cancervic.org.au>
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and introduction</td>
<td>i</td>
</tr>
<tr>
<td>Summary</td>
<td>1</td>
</tr>
<tr>
<td>Intent of the optimal care pathways</td>
<td>5</td>
</tr>
<tr>
<td>Optimal care pathway resources</td>
<td>6</td>
</tr>
<tr>
<td>Principles of the optimal care pathway</td>
<td>8</td>
</tr>
<tr>
<td>Principle 1: Patient-centred care</td>
<td>8</td>
</tr>
<tr>
<td>Principle 2: Safe and quality care</td>
<td>10</td>
</tr>
<tr>
<td>Principle 3: Multidisciplinary care</td>
<td>11</td>
</tr>
<tr>
<td>Principle 4: Supportive care</td>
<td>12</td>
</tr>
<tr>
<td>Principle 5: Care coordination</td>
<td>14</td>
</tr>
<tr>
<td>Principle 6: Communication</td>
<td>15</td>
</tr>
<tr>
<td>Principle 7: Research and clinical trials</td>
<td>17</td>
</tr>
<tr>
<td>Summary – optimal timeframes</td>
<td>18</td>
</tr>
<tr>
<td>Optimal care pathway</td>
<td>19</td>
</tr>
<tr>
<td>Step 1: Prevention and early detection</td>
<td>19</td>
</tr>
<tr>
<td>Step 2: Presentation, initial investigations and referral</td>
<td>21</td>
</tr>
<tr>
<td>Step 3: Diagnosis, staging and treatment planning</td>
<td>25</td>
</tr>
<tr>
<td>Step 4: Treatment</td>
<td>31</td>
</tr>
<tr>
<td>Step 5: Care after initial treatment and recovery</td>
<td>39</td>
</tr>
<tr>
<td>Step 6: Managing recurrent, residual or metastatic disease</td>
<td>45</td>
</tr>
<tr>
<td>Step 7: End-of-life care</td>
<td>49</td>
</tr>
<tr>
<td>Contributors and reviewers</td>
<td>52</td>
</tr>
<tr>
<td>Appendix A: Supportive care domains</td>
<td>54</td>
</tr>
<tr>
<td>Appendix B: Psychological needs</td>
<td>55</td>
</tr>
<tr>
<td>Appendix C: Special population groups</td>
<td>56</td>
</tr>
<tr>
<td>Appendix D: Complementary therapies</td>
<td>62</td>
</tr>
<tr>
<td>Appendix E: Members of the multidisciplinary team for melanoma</td>
<td>63</td>
</tr>
<tr>
<td>Resource list</td>
<td>64</td>
</tr>
<tr>
<td>Glossary</td>
<td>68</td>
</tr>
<tr>
<td>References</td>
<td>70</td>
</tr>
</tbody>
</table>
Welcome and introduction

On behalf of the optimal care pathways team, welcome to the second edition of the optimal care pathway guides to better cancer care.

Some cancers are simple to treat; many are complex. But the principles of high-quality care are similar for all cancers and, if followed, are likely to achieve the best outcomes for patients and their families and carers.

Australia has an excellent healthcare system, but the pathway for cancer patients can be complex. Often multiple health professionals are involved and both public and private types of health care are used. Our cancer survival rates are as good as anywhere in the world, but many patients still report difficulties during their care and, importantly, outcomes among different groups vary across the country.

That’s why we have developed the optimal care pathways. The optimal care pathways describe an integrated model of cancer care that puts the patient’s needs first, along with the best of technical care. They provide a national standard for the high-quality cancer care that all Australians should expect. We all believe when it comes to cancer care, our patients and their families deserve the best care available.

The optimal care pathways should be read and understood by all those involved in cancer care. This includes all health professionals, from surgeons, oncologists, haematologists, radiologists, general practitioners and other doctors to allied health professionals, nurses and managers of cancer services. Trainees in all disciplines should absorb the messages contained in the optimal care pathways.

We also recommend the optimal care pathways to all people affected by cancer, both patients and carers. We encourage you to use the optimal care pathways to guide discussions with your healthcare team and to help you make informed decisions about what’s right for you. There is a specific optimal care pathway for Aboriginal and Torres Strait Islander people, while the Guides to best cancer care for consumers are available in eight languages.

The optimal care pathways are endorsed by Cancer Australia, the National Cancer Expert Reference Group (a committee that reports to the Australian Health Ministers Advisory Committee and, through this committee, to the Council of Australian Governments Health Council) and all states and territories. The optimal care pathways have Australia-wide acceptance and government support.

It’s important to note that the optimal care pathways are cancer pathways, not clinical practice guidelines. The decision about ‘what’ treatment is given is a professional responsibility and will usually be based on current evidence, clinical practice guidelines and the patients’ preferences.

The optimal care pathways were updated in 2020, at a time when the global COVID-19 pandemic was challenging the Australian healthcare sector in an unprecedented way. The pandemic led to rapid practice change, including greater uptake of telehealth. Where appropriate, learnings have informed the review of the pathways.

I would like to thank everyone involved for their generous contribution to the development and revision of the optimal care pathways. This includes many health professionals (noted in the optimal care pathways) and the strong support of federal and state governments.

Professor Robert J S Thomas OAM
Chair, Optimal Care Pathways Project Steering Committee
Summary

The optimal care pathways describe the standard of care that should be available to all cancer patients treated in Australia. The pathways support patients and carers, health systems, health professionals and services, and encourage consistent optimal treatment and supportive care at each stage of a patient’s journey. Seven key principles underpin the guidance provided in the pathways: patient-centred care; safe and quality care; multidisciplinary care; supportive care; care coordination; communication; and research and clinical trials.

This quick reference guide provides a summary of the Optimal care pathway for people with melanoma.

Please note that not all patients will follow every step of the pathway.

Step 1: Prevention and early detection

**Prevention**
When the UV index levels are 3 or above (during sun protection times), people should be encouraged to use a combination of sun protection measures to avoid relying on one form of sun protection and to minimise UV exposure. These measures include wearing long-sleeved clothing, a broad-brimmed hat and sunglasses, applying an SPF30 or higher broad-spectrum sunscreen, and seeking out shade. People should also be encouraged to avoid using solariums and to protect children from sunburn and long-term exposure to the sun.

**Risk factors**
- A personal history of melanoma or non-melanoma skin cancer
- A family history of melanoma
- Increased numbers of naevi on a total body count (> 100 of more than 2 mm)
- Increased numbers of dysplastic naevi
- Solarium use
- A fair complexion (including fair skin with poor tanning ability, light or red-coloured hair and blue or green eyes)
- A history of blistering sunburn
- Multiple solar keratoses
- High levels of intermittent sun exposure (e.g. during outdoor recreation or sunny holidays)
- Immune suppression and/or transplant recipients
- Increasing age

**Screening**
Population screening is not appropriate for melanoma. However, high-risk patients should have regular total body cutaneous examinations.

**Managing increased risk**
- Education about skin self-examination and sun protection advice
- Total skin check every six to 12 months
- Use of surveillance photography
- Sequential dermoscopic imaging
- Referral to a dermatologist or cancer geneticist for people with a family history of cancer in two first-degree relatives

Checklist
- Education on skin self-examination provided
- Total skin check conducted for high-risk patients
- Recent weight changes discussed and the patient’s weight recorded
- Alcohol intake discussed and recorded and support for reducing alcohol consumption offered if appropriate
- Smoking status discussed and recorded and brief smoking cessation advice offered to smokers
- Physical activity recorded
- Referral to a dietitian considered
- Referral to a physiotherapist or exercise physiologist considered
- Education on being sun smart considered

Step 2: Presentation, initial investigations and referral

A change in one or more of the ABCDE criteria (asymmetry, border irregularity, colour, diameter of the skin, evolution) and/or the following should be investigated:
- Itching, scaling, bleeding, oozing, swelling or pain in a skin lesion
- New lesions, any changing skin lesions or lesions that do not heal or respond to treatment
- A rapidly growing skin lesion that persists after one month
- Spread of pigment from a lesion to the surrounding tissue.

Note: A small percentage of cases present as a symmetrical, often non-pigmented nodule that grows progressively for over a month (EFG: elevated, firm and growing progressively).

Checklist
- Signs and symptoms recorded
- Biopsy conducted and tissue sent to pathologist for examination
- Patient referred to a dermatologist, skin cancer GP or surgeon, if appropriate

Support: Assess supportive care needs at every step of the pathway and refer to appropriate health professionals or organisations.
Step 2: Presentation, initial investigations and referral

Initial investigations
Assessments should include taking a lesion history focusing on: how long the lesion has been present; time course if it has changed; the type of change; and associated symptoms (tender, itch, bleeding). Examinations should be undertaken with good lighting, using a dermatoscope. Observation, with review, should only occur if there is a low level of suspicion, and only for macular (flat) lesions (to avoid monitoring a nodular melanoma), using dermatoscopic imaging.

Where there is a high level of suspicion, the practitioner should either refer to a specialist or undertake an excisional biopsy. In general, complete excision of the entire lesion with a 2 mm margin should be performed.

If referral is considered the patient should be referred to a dermatologist, skin cancer GP or surgeon who can perform the biopsy.

The following lesions should be referred to a specialist:
- high-risk melanoma (deeply invasive > 1 mm)
- metastatic melanoma
- lesions with histologic uncertainty
- incompletely excised lesions that cannot be treated definitively in primary care.

Referral options
At the referral stage, the patient’s GP or other referring doctor should advise the patient about their options for referral, waiting periods, expertise, if there are likely to be out-of-pocket costs and the range of services available. This will enable patients to make an informed choice of specialist and health service.

Communication
The GP’s responsibilities include:
- explaining the diagnosis and the prognostic implications in broad terms
- explaining to the patient and/or carer who they are being referred to and why
- supporting the patient and/or carer while waiting for specialist appointments
- reassuring the patient that if the lesion is a melanoma and completely excised that a short delay to specialist review and treatment is not harmful
- informing the patient and/or carer that they can contact Cancer Council on 13 11 20.

Checklist continued
- Supportive care needs assessment completed and recorded, and referrals to allied health services actioned as required
- Patient notified of support services such as Cancer Council 13 11 20
- Referral options discussed with the patient and/or carer including cost implications

Timeframe
If melanoma is suspected, a biopsy or excision should be done within 2 weeks of the initial GP consult, and results provided to the patient within 1 week of the biopsy.

Where appropriate, referral to a specialist should occur within 2 weeks. There will be some patients where management in primary care is appropriate.

Step 3: Diagnosis, staging and treatment planning

Diagnosis
All patients should have a complete skin check.

Most diagnoses occur in the primary care setting.

Specialist management may include complete excision (in rare instances where a punch, shave or incisional biopsy was performed pre-referral) or re-excision with recommended margins, and imaging.

Staging
Sentinel lymph node biopsy should be considered for patients with a melanoma greater than 1 mm in thickness and for patients with a melanoma greater than 0.75 mm and other high-risk features such as ulceration; this will provide optimal staging and prognostic information. If metastatic melanoma is detected, discuss how to manage the regional lymph nodes region.

The options are observation with clinical and ultrasound review or completion lymph node dissection (CLND). CLND does not offer any survival benefit over close observation. A subset of patients who have metastatic melanoma detected in the sentinel nodes are likely to be referred to a medical oncologist to discuss the role of adjuvant systemic therapy.

Genetic testing
Patients that may be appropriate for referral include:
- people with more than one first-degree relative with melanoma – they should be referred to a dermatologist for a clinical risk assessment
- people with three or more relatives with melanoma and/or pancreatic cancer – they should be referred to a family cancer service for a genetic risk assessment.

Treatment planning
The multidisciplinary team should meet to discuss patients with unusual pathology, any patient where treatment may be unclear and all patients with stage III and IV disease, within 4 weeks of the initial diagnosis.

Checklist
- Diagnosis and staging confirmed
- Full histology obtained
- Performance status and comorbidities measured and recorded
- Patient discussed at an MDM and decisions provided to the patient and/or carer
- Clinical trial enrolment considered
- Supportive care needs assessment completed and recorded, and referrals to allied health services actioned as required
- Patient referred to support services (such as Cancer Council) as required
Step 3: Diagnosis, staging and treatment planning continued

Research and clinical trials
Consider enrolment where available and appropriate. Search for a trial <www.australiancancertrials.gov.au>.

Communication
The lead clinician's responsibilities include:
- discussing a timeframe for diagnosis and treatment options with the patient and/or carer
- explaining the role of the multidisciplinary team in treatment planning and ongoing care
- encouraging discussion about the diagnosis, prognosis, advance care planning and palliative care while clarifying the patient's wishes, needs, beliefs and expectations, and their ability to comprehend the communication
- providing appropriate information and referral to support services as required
- communicating with the patient's GP about the diagnosis, treatment plan and recommendations from multidisciplinary meetings (MDMs).

Checklist continued
- Patient referred to a familial cancer service, if appropriate
- Treatment costs discussed with the patient and/or carer

Timeframe
Staging investigations should be completed within 2 weeks of the specialist's assessment.

Step 4: Treatment

Establish intent of treatment
- Curative
- Loco-regional control
- Anti-cancer therapy to improve quality of life and/or longevity without expectation of cure
- Symptom palliation

Full skin assessment is a preliminary treatment option to assess the risk of further melanomas, for surveillance planning and to detect synchronous primaries, and/or other keratinocytic skin cancers that may require intervention.

Surgery with direct primary closure can be undertaken in a primary care setting for excision biopsy and selected re-excision for in situ and early-stage melanomas. Surgery for all other excisions (including sentinel lymph node biopsy and regional lymphadenectomy) should be undertaken by a surgeon with adequate training and experience.

Radiation therapy may benefit in the following circumstances: definitive treatment for in situ melanoma in medically inoperable areas or for patients where a complete resection would be prohibitively morbid; adjuvant radiation therapy following surgical resection for invasive melanoma with a high risk of recurring if potentially effective systemic therapy is not available; and for palliative treatment.

Systemic therapy should be considered for select patients with stage III melanoma (confined to regional lymph nodes) and all patients with advanced melanoma (stage IV) given their potential improvement in progression-free survival and overall survival. Options include immunotherapy and targeted therapy.

Palliative care:
For patients who are not responding to treatment or with very advanced disease, early referral to palliative care can improve quality of life and in some cases survival. Referral should be based on need, not prognosis. For more, visit the Palliative Care Australia website <www.palliativecare.org.au>.

Communication
The lead clinician and team’s responsibilities include:
- discussing treatment options with the patient and/or carer including the intent of treatment as well as risks and benefits
- discussing advance care planning with the patient and/or carer where appropriate
- communicating the treatment plan to the patient’s GP
- helping patients to find appropriate support for exercise programs where appropriate to improve treatment outcomes.

Checklist
- Intent of treatment established
- Advantages and disadvantages of treatments discussed with the patient and/or carer
- Treatment plan discussed with the patient and/or carer and provided to the patient’s GP
- Treating specialist has adequate qualifications, experience and expertise
- Supportive care needs assessment completed and recorded, and referrals to allied health services actioned as required
- Early referral to palliative care considered
- Advance care planning discussed with the patient and/or carer

Timeframe
Surgery in a primary care setting should occur within 2 weeks of the decision that it is necessary. If not urgent, radiation therapy should begin within 4 weeks of the MDM.

Systemic therapy: as adjuvant therapy, should occur within 12 weeks of definitive surgery; and to treat stage IV disease, should begin as soon as clinically relevant, ideally within 4 weeks.

Support: Assess supportive care needs at every step of the pathway and refer to appropriate health professionals or organisations.

1 Lead clinician – the clinician who is responsible for managing patient care. The lead clinician may change over time depending on the stage of the care pathway and where care is being provided.
Step 5: Care after initial treatment and recovery

Provide a treatment and follow-up summary to the patient, carer and GP outlining:
- the diagnosis, including tests performed and results
- melanoma characteristics, specifically the primary thickness and whether ulceration is present
- treatment received (types and date)
- current toxicities (severity, management and expected outcomes)
- interventions and treatment plans from other health professionals
- potential long-term and late effects of treatment and care of these
- supportive care services provided

- a follow-up schedule, including tests required and timing
- contact information for key healthcare providers who can offer support for lifestyle modification
- a process for rapid re-entry to medical services for suspected recurrence.

Communication
The lead clinician’s responsibilities include:
- explaining the treatment summary and follow-up care plan to the patient and/or carer
- informing the patient and/or carer about secondary prevention and healthy living
- discussing the follow-up care plan with the patient’s GP.

Step 6: Managing recurrent, residual or metastatic disease

Detection
Self-examination is essential for any new or changing skin lesion, cutaneous lump or persistent new symptom. Metastatic disease will be detected most commonly by the patient presenting with symptoms and less commonly via routine follow-up.

Treatment
Evaluate each patient for whether referral to the original multidisciplinary team is appropriate. Treatment will depend on the location and extent of disease, previous management and the patient’s preferences.

Advance care planning
Advance care planning is important for all patients but especially those with advanced disease. It allows them to plan for their future health and personal care by thinking about their values and preferences. This can guide future treatment if the patient is unable to speak for themselves.

Survivorship and palliative care
Survivorship and palliative care should be addressed for patients with recurrent melanoma or melanoma that has had metastasised. Early referral to palliative care can improve quality of life and in some cases survival. Referral should be based on need, not prognosis.

Communication
The lead clinician and team’s responsibilities include:
- explaining the treatment intent, likely outcomes and side effects to the patient and/or carer and the patient’s GP.

Step 7: End-of-life care

Palliative care
Consider a referral to palliative care. Ensure an advance care directive is in place.

Communication
The lead clinician’s responsibilities include:
- being open about the prognosis and discussing palliative care options with the patient
- establishing transition plans to ensure the patient’s needs and goals are considered in the appropriate environment.

Checklist
- Treatment and follow-up summary provided to the patient and/or carer and the patient’s GP
- Importance of skin self-examination and sun protection discussed with the patient and/or carer
- Supportive care needs assessment completed and recorded, and referrals to allied health services actioned as required
- Patient-reported outcome measures recorded

Intent of the optimal care pathways

Optimal care pathways map seven key steps in cancer care. Each of these steps outlines nationally agreed best practice for the best level of care. While the seven steps appear in a linear model, in practice, patient care does not always occur in this way but depends on the particular situation (e.g., the type of cancer, when and how the cancer is diagnosed, prognosis, management, the patient’s decisions and their physiological response to treatment).

The principles underpinning optimal care pathways always put patients at the centre of care throughout their experience and prompt the healthcare system to deliver coordinated care.

The optimal care pathways do not constitute medical advice or replace clinical judgement, and they refer to clinical guidelines and other resources where appropriate.

Figure 1: The optimal care pathway

Screening and referral to supportive care should be considered throughout all cancer care.
Optimal care pathway resources

There are three resources for each pathway: an optimal care pathway, a quick reference guide for health professionals and a guide to best cancer care for patients, carers and families.

Optimal care pathways

This optimal care pathway is designed for health professionals and health services. However, patients and carers may find useful information in this version to help understand the processes their treating health professionals are following.

The resource aims to:

- assist health professionals to provide optimal care and support to patients with cancer, their families and carers
- provide optimal timeframes for delivering evidence-based care
- emphasise the importance of communication and collaboration between health providers and people affected by cancer
- assist and inform new health professionals or trainees who are entering the cancer care workforce
- provide value to health systems to identify gaps in current cancer services, bring about quality improvement initiatives and improve how services are planned and coordinated.

Adherence to the pathways should be measured wherever possible.

Visit the Cancer Council website <www.cancer.org.au/OCP> to view the optimal care pathways.

Quick reference guides

The quick reference guides are for health professionals and health services. They provide a summary of each optimal care pathway for health professionals and patients.

The quick reference guides include:

- optimal timeframes within which tests or procedures should be completed
- checklists with indicators related to recommendations in the optimal care pathway.

Visit the Cancer Council website <www.cancer.org.au/OCP> to view the quick reference guide for this optimal care pathway.
Guides to best cancer care

The guides to best cancer care are consumer resources that help patients understand the optimal cancer care that should be provided at each step. Carers, family and friends may also find the guides helpful.

The guides to best cancer care:

- include optimal timeframes within which tests or procedures should be completed
- include prompt questions to support patients to understand what might happen at each step of their cancer journey and to consider what questions to ask
- provide information to help patients and carers communicate with health professionals
- are available in eight languages.

Visit the Cancer Council's website <www.cancercareguides.org.au> to view the guides to best cancer care.

Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer

The Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer provides a tool to help reduce disparities and improve outcomes and experiences for Aboriginal and Torres Strait Islander people with cancer. This resource can be used in conjunction with the optimal care pathway for each cancer type.

Visit the Cancer Australia website <https://www.canceraustralia.gov.au/affected-cancer/atsi/resources-health> to view the optimal care pathway for Aboriginal and Torres Strait Islander people.
Principles of the optimal care pathway

The seven principles of care define appropriate and supportive cancer care that is the right of all patients and the right of those caring for and connected with them.

Figure 2: The seven principles underpinning the optimal care pathway

**Principle 1: Patient-centred care**

Patient-centred care informs and involves patients in their care and respects and responds to the preferences, needs and values of patients, families and carers.

A patient-centred focus increases the experience and satisfaction of patients, their families and carers, and staff, as well as safety and cost-effectiveness (ACSQHC 2019a).

Patient-centred care means:

- patients are informed and involved in decisions about their cancer and the treatment, post-treatment and recovery program ahead
- patients, their families and carers are provided with access to appropriate and accessible health information
- respect for the cultural and religious beliefs of patients and their families is demonstrated when discussing the diagnosis of cancer
- active communication is used to engage patients, their families and carers in the care process – an essential step for patients to be informed
- care processes are mutually beneficial for patients and providers
- special needs are addressed – for example, the needs of people with disabilities or mental health issues.
Informed choice and consent

An informed patient has greater confidence and competence to manage their cancer journey.

Health professionals are responsible for enabling patients to make informed choices according to their preferences, needs and values. Patients should be provided with:

- individualised and timely information and guidance about their treatment
- details of their care, including the advantages and disadvantages of each treatment, the associated potential side effects, the likely outcomes on their performance status (how well a patient is able to carry out activities of daily life) and subsequently their quality of life and any financial implications, at each stage of the pathway (ACSQHC 2020).

Health professionals have a legal responsibility to obtain consent for all procedures from either the patient or their substitute decision-maker if they are not deemed competent.

Referral choices and informed financial consent

Patients have the right to receive the information they need to be able to make an informed decision on where to be referred for treatment. Treating specialists and practitioners should clearly explain the costs or how to find out the costs of services, tests and treatment options upfront to avoid consumers experiencing ‘bill shock’.

At the time of referral, the patient’s general practitioner or other referring doctor should discuss the different options for referral, waiting periods, expertise, if there are likely to be out-of-pocket costs and the range of services available. This will enable patients to make an informed choice of specialist and health service. Referral decisions influence the care patients receive along the pathway and the direct and indirect costs they and their carers may incur. Different referrals have different costs:

- referral to a public hospital, which may involve some costs
- initial referral to a private specialist with associated costs, with the option of ongoing treatment in a public hospital at any time
- referral to a patient’s choice of practitioner for immediate and ongoing private hospital management with associated costs.

Patients should be made aware that even though public hospital health care is ‘free’ to all Australian citizens and most permanent residents of Australia, there are still associated direct costs such as:

- over-the-counter medication and prescriptions
- wound dressings
- travel costs
- parking fees
- tests that are not covered by Medicare.

A cancer diagnosis and treatment may affect a patient’s or carer’s income. This is an indirect cost associated with cancer. Social work support is essential to help patients and their families deal with this issue. Patients should be advised not to undergo private care with significant out-of-pocket expenses if financially constrained. Specialists in private practice need to explain costs at the start of each new treatment to acknowledge the cumulative out-of-pocket expenses that patients can incur.

Financial counselling services can provide advice on dealing with financial difficulties. These services can be accessed publicly (via social workers at hospitals, financial counsellors at neighbourhood houses or rural financial aid), privately or through cancer support services such as local charity groups or social work services.


**Shared care**

Shared care between a cancer specialist and primary care health professional is delivered in two or more settings by two or more professionals. The primary care provider is usually a general practitioner but can include nurses and allied health practitioners. Shared care can be delivered throughout the care pathway including during treatment, follow-up care, survivorship care and end-of-life care.

Shared care offers several advantages to patients, including the potential for treatment closer to home and more efficient care with less duplication and greater coordination. Evidence comparing shared care and specialised care indicates equivalence in outcomes including recurrence rate, cancer survival and quality of life (Cancer Research in Primary Care 2016).

Telehealth can enable efficient shared care and should be explored for all patients. Patients in some rural or remote locations may access specialists via Medicare Benefit Scheme funded telehealth consultations. General practitioners working in rural or remote locations should be aware of specialist multidisciplinary teams with facilities to reduce the travel burden and costs for patients.

**Principle 2: Safe and quality care**

Hospitals and health professionals are responsible for providing safe and quality care.

Health professionals need to have appropriate training and experience to undertake treatment for melanoma. The required experience will depend on the stage of the disease; the patient should be referred to an individual practitioner or service with appropriate expertise.

Safe and high-quality care is care provided by appropriately trained and credentialed health professionals who undertake regular quality reviews of their performance, contribute to regular audits of their care and are actively involved in continuing professional development. Hospitals and clinics must have the equipment, staff numbers, policies and procedures in place to support safe and high-quality care for cancer patients. Patients should be offered the safest options for care, which may include using telehealth (Cancer Australia 2020a).

Hospital quality committees should ensure all health care is informed by evidence, and health professionals and health service managers (including executives) have a responsibility to evaluate and monitor their practice. Optimal care pathways provide a framework to help evaluate and monitor practice over time. Services should be routinely collecting relevant minimum datasets to support benchmarking, quality care and service improvement. Hospital committees and health professional peak bodies should be auditing this process (ACSQHC 2017, 2020).

The Australian Council on Health Standards <https://www.achs.org.au/> has created a set of indicators that helps hospitals conform to appropriate standards.
Patient-reported experience and outcome measures

Patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs) should be incorporated into routine cancer care.

PREMs are used to obtain patients’ views and observations on aspects of healthcare services they have received (AIHW 2018). Patient experience data is collected for specific services and then relayed to service providers to instigate improvements in patient services (ACSQHC 2019b).

The Australian Hospital Patient Experience Question Set (AHPEQS) is a tool used to assess patient experiences of treatment and care in a private or public hospital. AHPEQS helps to improve the safety and quality of health care by allowing organisations to understand the patient’s perspective (AIHW 2018; ACSQHC 2019b).

PROMs measure aspects of a person’s health status such as symptoms, quality of life and needs and are collected directly from patients either online, via a smartphone or through paper-based means.

Collecting PROMs, and then instigating an appropriate clinical response, has been shown to prolong survival, reduce health system use and improve patients’ quality of life. While there are many sets of PROMs questions that are relevant to any cancer patient, specific questions can be tailored to particular cancer types, populations or different phases of cancer care.

Principle 3: Multidisciplinary care

Multidisciplinary care is an integrated team approach that involves all relevant health professionals discussing all relevant treatment options and making joint recommendations about treatment and supportive care plans, taking into account the personal preferences of patients.

Multidisciplinary care improves patient outcomes. Cancer Australia’s ‘Principles of multidisciplinary care’ provides a flexible definition, allowing services to vary implementation according to cancer type and the service location. The principles stipulate:

- a team approach that involves core disciplines that are integral to providing good care, including general practice, with input from other specialties as required
- communication among team members about treatment planning and plans for follow-up
- access to the full therapeutic range for all patients, regardless of geographical remoteness or size of institution
- care delivery in accordance with nationally agreed standards
- patient involvement in decisions about their care (Cancer Australia 2019a).

In addition to these principles, treatment teams should consider clinical trial participation for all eligible patients.

Multidisciplinary meetings, often called MDMs, should be based on the principles outlined above.

Principle 4: Supportive care

Supportive care is a vital part of any cancer treatment program. Supportive care deals with issues that emerge for patients, families and carers from the effects of the cancer diagnosis and its treatment. It is made up of all the services, information and resources patients may need to meet their physical, psychological, social, information and spiritual needs from the time of diagnosis.

Supportive care may be ‘patient-defined’ and based on unmet needs. It is a core component of evidence-based clinical care and its benefits are well established. All cancer patients and their carers should be formally supported and have access to understandable, relevant information about the medical, practical and emotional aspects of the cancer and its treatment (Fitch 2008). The wishes and needs of the patient, their family and their carers should determine the level of support provided. Supportive care is a standard or routine aspect of cancer care and the treatment team should make patients aware of this.

Supportive care should begin from the time of diagnosis and continue throughout the cancer pathway.

For health professionals, supportive care involves:

- screening and assessing patients and families for their supportive care needs
- providing patients with access to a range of multidisciplinary support services, groups and therapies designed to assist them to live with cancer and its treatment and optimise recovery
- optimising referral pathways to community support organisations (cancer-related non-government, not-for-profit and charities) that provide services to cancer survivors – these address many of the care-navigation, psychosocial and information needs of cancer survivors and those affected by cancer (Australian Cancer Survivorship Centre 2019)
- being aware of and delivering culturally appropriate care.

All members of the multidisciplinary team have a role in providing supportive care along the care pathway, with special attention at transition points.

Supportive care involves routinely and systematically assessing patients to determine their needs. Health professionals can use a variety of validated screening tools for this task (see box on page 13). Clinical review and individual assessment are still required to ensure all patient concerns are identified.

More information

Visit the WeCan website <www.wecan.org.au> for information and resources on supportive care.
Validated screening tools

- National Comprehensive Cancer Network Distress Thermometer and Problem Checklist
- Supportive Care Needs Assessment Tool for Indigenous People (SCNAT-IP).

Key review points

The treatment team should assess patients for supportive care needs at these key stages:

- initial presentation or diagnosis (first three months)
- the beginning of treatment or a new phase of treatment
- change in prognosis
- if a patient is found to have a germline genetic mutation predisposing to cancer
- end of treatment
- throughout survivorship
- diagnosis of recurrence
- change in or development of new symptoms
- palliative care
- end-of-life care
- other time points based on clinical judgement.

The team also needs to decide whether the patient requires ongoing referral to supportive care services. Access to services can be through general practice-led chronic disease management plans, team care arrangements and mental health plans. Community support services also have a role to play.

See Appendices A, B and C for more information on supportive care and the specific needs of people that may arise.
Principle 5: Care coordination

Care coordination is the responsibility of every professional, both clinical and non-clinical, who works with patients, their families and carers.

Seamless care coordination is essential for patients to successfully navigate the complex health system. Care coordination is a comprehensive approach to achieving continuity of care for patients. It aims to ensure care is delivered in a systematic, connected and timely way that promotes efficiency and reduces the risk of duplication and over-servicing to meet the medical and personal needs of patients.

Care coordination includes:

- proactive and timely communication with patients, their families and carers
- treatment plans, survivorship care plans and/or advance care directives
- coordinated appointments to ensure timely diagnosis, treatment and survivorship care
- appropriate tests and results being available to the treating team so treatment decisions can be made
- medical records being available to all members of the treating team and at scheduled appointments
- translation or interpreter services arranged if the patient/carer is from a non-English speaking background or has difficulty communicating due to a physical disability
- practical support such as transport, accommodation, advance care planning and financial support
- referral and access to supportive care
- access to clinical trials
- access to telehealth for people in rural and remote areas and for managing vulnerable patients.

Care coordination brings together different health professionals, teams and health services. It also encompasses MDMs, multidisciplinary assessment clinics, supportive care screening and assessment, referral practices, data collection, common protocols, information for patients and individual clinical treatment.

Care coordination should cross the acute and primary care interface and should aim to achieve consistency of care through clear communication, linkages and collaborative integrated care planning.

Care coordination can be facilitated through electronic health record management such as My Health Record. My Health Record is a secure online database that helps with data collection and care coordination (My Health Record 2019).

Formal care coordination through appointed care coordinators plays an important role in managing and supporting patients through the health system. The availability of dedicated care coordinators varies across states and territories according to the complexity of care required and local service capacity and resourcing.
Principle 6: Communication

Everyone employed in the healthcare system is responsible for ensuring the communication needs of patients, their families and carers are met.

Good and open communication is a key principle of care for cancer patients. This includes communication between oncology and primary care health professionals and with patients. General practitioners should be involved in care from the point of diagnosis, and patients should be encouraged to maintain a relationship with their general practitioner through all stages of cancer care. Communication should be regular and timely.

Attendance of a family member or carer at clinical appointments is beneficial for many patients, as the family member or carer can provide informational and emotional support. General practitioners and clinicians should encourage and support the involvement of family members and carers by providing an inclusive and supportive consultation environment (Laidsaar-Powell et al. 2018a). Laidsaar-Powell et al. provide evidence-based guidance on how to support family member or carer involvement in consultations (Laidsaar-Powell et al. 2018a, 2018b).

Every person with cancer will have different communication needs, including cultural and language differences. When anyone involved in treatment communicates with patients, they should be truthful and transparent but aware of cultural and psychological sensitivities. In communicating with patients, healthcare providers should undertake to:

- empower patients to be active in treatment discussions
- use professionally trained interpreters if required – for example, when communicating with people from culturally diverse backgrounds whose primary spoken language is not English and for people with a hearing impairment (visit the Translating and Interpreting Services website <www.tisnational.gov.au> for more information on interpreter and language services)
- use culturally sensitive and appropriate forums of communication for people from culturally diverse backgrounds and Aboriginal and Torres Strait Islander people, as appropriate
- provide appropriate information for people from culturally diverse backgrounds
- provide information on community-based supportive care services and resources to patients and their families and carer
- identify the patient’s substitute treatment decision-maker to ensure they are involved in relevant discussions
- ensure patients, their families or their carers have the opportunity to ask questions
- seek consent before conveying information between health professionals or healthcare teams or with family and carers
- be respectful if a patient seeks a second opinion from another health professional
- ensure patients do not have to convey information between areas of care (it is the provider’s and healthcare system’s responsibility to transfer information between areas of care)
- communicate in plain language (avoiding complex medical terms and jargon)
- ensure information is communicated at a level relevant to the patient’s health literacy and that of their families and carers (ACSQHC 2020)
- use tools, diagrams and aids as appropriate (Gilligan et al. 2017)
- ensure the patient is aware of how to access electronic patient information, where appropriate
allow enough time for communication, especially when conveying complex or sensitive information such as an initial diagnosis

check the patient’s and/or their family or carer’s understanding by asking the patient and/or their family or carer to say in their own words what has been conveyed.

Healthcare providers should also consider offering patients a question prompt list before a consultation and recordings or written summaries of their consultations afterwards. Question prompt lists are effective in improving communication and the psychological and cognitive outcomes of cancer patients. Recordings or summaries of key consultations improve patients’ recall of information and satisfaction (Hack et al. 2012). Written care plans, treatment summaries, survivorship care plans and advance care directives are effective records and communication tools.

Communication skills training programs that use role-play to develop skills and observe patient interactions to provide feedback, should be available to health professionals at every level of practice (Gilligan et al. 2017).

Communication skills training programs and resources can be found on the following websites:

- eviQ <https://education.eviq.org.au>
- VITAL talk <www.vitaltalk.org>.

Telehealth has become an increasingly acceptable alternative to face-to-face consultations. When using telehealth, the team must consider what is best for the patient, including the patient’s preferences of the patient. A face-to-face consultation should be the first option, if it is safe, when delivering critical diagnosis information, a change in therapy or prescribing intensive treatment. If this is not an option, a video consultation should be considered, and the patient should be encouraged to have a support person with them to assist (Cancer Australia 2020a).
Principle 7: Research and clinical trials

Research and clinical trials play an important role in establishing the efficacy and safety of diagnostic, prognostic and therapeutic interventions, as well as establishing the role of psychological, supportive care and palliative care interventions (Sjoquist & Zalcberg 2013).

Clinical trials are the foundation for improved cancer outcomes, allowing new treatments to be tested and offering patients access to potentially more effective therapies than otherwise available to them.

Clinical trials are available for multiple types of cancer and may be a valuable option for people with rare, difficult-to-treat conditions for which there may be limited evidence about how the condition is best treated or managed (Australian Clinical Trials 2015).

Treating specialists and multidisciplinary teams should be aware of or search for clinical trials that may be suitable for their patients. Specialists should be willing to refer appropriate patients to other treating centres to participate in research or clinical trials at any stage of the care pathway and be willing to discuss the pros and cons of participating in such trials. Any member of the multidisciplinary team can encourage cross-referral between clinical trials centres. Possible ineligibility to participate in a clinical trial should be discussed with the patient. Acknowledge disappointment and offer support in this instance.

Health services should strive to implement policies and procedures that facilitate equitable access to clinical trials for all patients, including culturally diverse patients, regional patients and those from Aboriginal or Torres Strait Islander communities.

The use of telehealth technology, such as the Australasian Tele-trial Model, hopes to improve access to trials for patients being treated in rural and regional areas (COSA 2016).

Australian Cancer Trials is a national clinical trials database. It provides information on the latest clinical trials in cancer care, including trials that are recruiting new participants. Search for a trial <www.australiancancertrials.gov.au> via its website.

Education and training

Research and clinical trials provide an opportunity to educate health professionals who are in training. Cancer centres may be affiliated with teaching hospitals, universities or research groups to promote higher education or to develop the academic workforce, leading to more sustainable practice. Specialists should be encouraged to take up and retain active membership to professional societies and organisations that can assist with professional development opportunities.
Summary – optimal timeframes

Evidence-based guidelines, where they exist, should inform timeframes. Treatment teams need to recognise that shorter timeframes for appropriate consultations and treatment can promote a better experience for patients. Three steps in the pathway specify timeframes for care (Figure 3). They are designed to help patients understand the timeframes in which they can expect to be assessed and treated, and to help health services plan care delivery in accordance with expert-informed time parameters to meet the expectation of patients. These timeframes are based on expert advice from the Melanoma Working Group.

Figure 3: Timeframes for care

<table>
<thead>
<tr>
<th>Step in pathway</th>
<th>Care point</th>
<th>Timeframe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation, initial investigations and referral</td>
<td>Signs and symptoms</td>
<td>Presenting symptoms should be promptly and clinically triaged with a general practitioner</td>
</tr>
<tr>
<td></td>
<td>Initial investigations initiated by GP</td>
<td>If melanoma is suspected, a biopsy or excision should be done within 2 weeks of the initial consult, and results should be provided to the patient within 1 week of the biopsy</td>
</tr>
<tr>
<td></td>
<td>Referral to specialist</td>
<td>Where appropriate, referral to a specialist should occur within 2 weeks</td>
</tr>
<tr>
<td></td>
<td></td>
<td>There will be some patients where management in primary care is appropriate</td>
</tr>
<tr>
<td>Diagnosis, staging and treatment planning</td>
<td>Diagnosis and staging</td>
<td>Staging investigations should be completed within 2 weeks of the specialist’s assessment</td>
</tr>
<tr>
<td></td>
<td>Multidisciplinary team meeting and treatment planning</td>
<td>Appropriate patients should be discussed at an MDM within 4 weeks of initial diagnosis</td>
</tr>
<tr>
<td>Treatment</td>
<td>Surgery</td>
<td>Surgery in a primary care setting should occur within 2 weeks of the decision that it is necessary</td>
</tr>
<tr>
<td></td>
<td>Radiation therapy</td>
<td>If not urgent, radiation therapy should begin within 4 weeks of the MDM</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Some patients will require urgent treatment</td>
</tr>
<tr>
<td></td>
<td>Systemic therapy</td>
<td>If systemic therapy is to be given as adjuvant therapy, this should occur within 12 weeks of the definitive surgery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If systemic therapy is to be given to treat stage IV disease, therapy should begin as soon as possible (as clinically indicated), ideally within 4 weeks</td>
</tr>
</tbody>
</table>
Optimal care pathway

Seven steps of the optimal care pathway
Step 1: Prevention and early detection
Step 2: Presentation, initial investigations and referral
Step 3: Diagnosis, staging and treatment planning
Step 4: Treatment
Step 5: Care after initial treatment and recovery
Step 6: Managing recurrent, residual or metastatic disease
Step 7: End-of-life care

In Australia, melanoma was estimated to be the third most commonly diagnosed cancer in 2020 (Cancer Australia 2020b). In 2019, Australian women were estimated to have a one in 21 chance of being diagnosed with melanoma before the age of 85, whereas men were estimated to have a one in 14 risk (AIHW 2019).

This pathway covers cutaneous melanomas. Ocular and periocular melanomas are not included in this pathway given the differences in the risk factors and management of these tumours.

Step 1: Prevention and early detection

This step outlines recommendations for the prevention and early detection of melanoma.

Evidence shows that not smoking, avoiding or limiting alcohol intake, eating a healthy diet, maintaining a healthy body weight, being physically active, being sun smart and avoiding exposure to oncoviruses or carcinogens may help reduce cancer risk (Cancer Council Australia 2018).

1.1 Prevention

Recommendations for preventing melanoma include:

- Avoid using solariums.
- Avoid getting sunburnt, especially to the point of blistering and skin peeling because multiple episodes have been shown to increase the risk of developing melanoma.
- Protect skin from the sun during sun protection times (when the ultraviolet [UV] levels are 3 or above) by using a combination of:
  - long-sleeved clothing
  - broad-brimmed hats
  - broad-spectrum sunscreens with an SPF of 30 or higher
  - sunglasses
  - seeking out shade.
- Always protect children from sunburn and long-term overexposure to the sun.

People should be encouraged to use a combination of sun protection measures to avoid reliance on one form of sun protection, and as an adjunct to minimising UV exposure.
1.2 Risk factors

The risk factors for developing melanoma include:

- a personal history of melanoma or non-melanoma skin cancer
- a family history of melanoma
- increased numbers of nevi on a total body count (> 100 of more than 2 mm)
- increased numbers of dysplastic naevi – people with more than 5 dysplastic nevi have a 10 times greater chance of developing melanoma than people who have no dysplastic nevi (NCI 2018)
- solarium use
- a fair complexion (including fair skin with poor tanning ability, light or red-coloured hair and blue or green eyes)
- a history of blistering sunburn
- multiple solar keratoses (Cancer Australia 2017a)
- high levels of intermittent sun exposure (e.g. during outdoor recreation or sunny holidays)
- immune suppression and/or transplant recipients
- increasing age.

Patients with an increased risk to develop melanoma should receive education from a general practitioner or dermatologist about skin self-examination and sun protection advice.

Patients with a high risk of developing melanoma may need:

- a total skin check every six to 12 months by a dermatologist or general practitioner with skills in dermoscopy
- surveillance photography (for people with multiple naevi)
- sequential dermoscopic imaging
- referral to a dermatologist or cancer geneticist for people with a family history of cancer in two first-degree relatives.

1.3 Early detection

1.3.1 Screening recommendations

Population screening is not appropriate for melanoma. However, opportunistic identification of high-risk patients and subsequent total body cutaneous examination of these patients should be practised (Cancer Council Australia Melanoma Guidelines Working Party 2019).

It is important for clinicians to be aware of high-risk groups and ensure that individuals in those groups are aware of their increased risk, establishing a surveillance program that includes regular total skin examinations (Cancer Council Australia Melanoma Guidelines Working Party 2019).
Step 2: Presentation, initial investigations and referral

This step outlines the process for the general practitioner to initiate the right investigations and refer to the appropriate specialist in a timely manner. The types of investigations the general practitioner undertakes will depend on many factors, including access to diagnostic tests, the availability of medical specialists and patient preferences.

2.1 Signs and symptoms

A skin lesion exhibiting features that match one or more of the ABCDE criteria should be investigated:

- asymmetry
- border irregularity
- colour
- diameter of the skin lesion
- evolving and/or the following:
  - itching, scaling, bleeding, oozing, swelling or pain in a skin lesion
  - new lesions, lesions noted to be changing or lesions that do not heal or respond to treatment
  - a rapidly growing skin lesion persistent after one month
  - spread of pigment from a lesion to the surrounding tissue.

The presence of multiple signs and symptoms, particularly in combination with other underlying risk factors, indicates an increased risk of melanoma.

Note: A small percentage of cases present as a symmetrical, often non-pigmented nodule that grows progressively for over a month (EFG: elevated, firm and growing progressively; Kelly et al. 2003). These are invasive from the outset and grow more quickly (over weeks to months), with elevation, deeper invasion and earlier onset of bleeding and ulceration.

2.1.1 Timeframe for general practitioner consultation

Presenting symptoms should be promptly and clinically triaged with a general practitioner.

2.2 Assessments by the general practitioner

For patients who present to their general practitioner, either for a routine skin examination or a lesion of concern, a systematic approach to assessment should be used. This entails taking a history with emphasis on lesion(s) of concern focusing on: how long the lesion has been present; time course if it has changed; type of change; and associated symptoms (tender, itch, bleeding). Examination should be undertaken with good lighting and with magnification, and with the aid of a dermatoscope (it is incumbent on the general practitioner to have acquired the knowledge and skill in the use of dermatoscopy).

The practitioner should classify the nature of the lesions, particularly common benign lesions (seborrheic keratosis, angioma, sebaceous hyperplasia). The distinction between naevus and early melanoma may be subtle. When uncertain, there should be a low threshold for referral for a second opinion or an appropriate biopsy.

Observation, with review, should only occur if there is a low level of suspicion, and only for macular (flat) lesions (to avoid monitoring a nodular melanoma), with monitoring best performed using dermatoscopic imaging. Patients should be educated and alerted that any visible change should lead to a faster review. If a review is planned the time interval should be no more than three months.
Where there is a high level of suspicion, the practitioner should either refer to a specialist or undertake an excisional biopsy. In general, complete excision of the entire lesion (with a 2 mm margin) should be performed to provide the pathologist with maximal tissue and allow the tumour architecture to be studied. Partial biopsy (shave, incisional) is appropriate when the lesion is very large, in a cosmetically sensitive location, or where biopsy will cause loss of function (Cancer Council Australia Melanoma Guidelines Working Party 2019). Where partial biopsy is used, the practitioner needs to be aware of the limitations of these techniques, which includes the potential for histological diagnostic errors (Cancer Council Australia Melanoma Guidelines Working Party 2019; Ng et al. 2010). A punch biopsy diagnosis that indicated a benign melanocytic lesion is not definitive and is inadequate. All biopsies must be submitted for histopathological examination by a pathologist.

If referral is considered the patient should be referred to a dermatologist, skin cancer general practitioner or surgeon who can perform the biopsy, ensuring the patient will be assessed within two weeks.


2.2.1 Timeframe for completing investigations

If melanoma is suspected, a biopsy or excision should be done within two weeks of the initial general practitioner consult, and results should be provided to the patient within one week of the biopsy.

2.3 Initial referral

The following lesions should be referred to a specialist with experience and expertise in melanoma:

- high-risk melanoma (deeply invasive > 1 mm)
- metastatic melanoma
- lesions with histological uncertainty
- incompletely excised lesions that cannot be treated definitively in primary care.

Patients should be enabled to make informed decisions about their choice of specialist and health service. General practitioners should make referrals in consultation with the patient after considering the clinical care needed, cost implications (see referral options and informed financial consent on page 9), waiting periods, location and facilities, including discussing the patient’s preference for health care through the public or the private system.

Referral for suspected or proven melanoma should include the following essential information to accurately triage and categorise the level of clinical urgency:

- important psychosocial history and relevant medical history
- family history, current symptoms, medications and allergies
- results of current clinical investigations (imaging and pathology reports)
- results of all prior relevant investigations
- history of previously treated melanoma
- notification if an interpreter service is required
- any relevant findings from a full skin examination.
Many services will reject incomplete referrals, so it is important that referrals comply with all relevant health service criteria.

If access is via online referral, a lack of a hard copy should not delay referral.

The specialist should provide timely communication to the general practitioner about the consultation and should notify the general practitioner if the patient does not attend appointments.

Aboriginal and Torres Strait Islander patients will need a culturally appropriate referral. To view the optimal care pathway for Aboriginal and Torres Strait Islander people and the corresponding quick reference guide, visit the Cancer Australia website <https://www.canceraustralia.gov.au/affected-cancer/atsi/resources-health>.


2.3.1 Timeframe for referring to a specialist
Where appropriate, referral to a specialist should occur within two weeks. There will be some patients where management in primary care is appropriate.

2.4 Support and communication
2.4.1 Supportive care
The patient’s general practitioner should consider an individualised supportive care assessment where appropriate to identify the needs of an individual, their carer and family. If the general practitioner is treating the patient, the patient should be appropriately counselled with respect to prognosis and risk of recurrence, along with advice on sun protection behaviours. If the general practitioner’s knowledge does not have the required depth, so long as the melanoma has been excised in the biopsy, the patient should be informed that a short delay to seeing a specialist will not be harmful. The general practitioner should outline to the patient the likely next step in management. Refer to appropriate support services as required. See validated screening tools mentioned in Principle 4 ‘Supportive care’.

Specific needs may arise for patients at this time:
• assistance for dealing with the emotional distress and/or anger of dealing with a potential cancer diagnosis, anxiety/depression, interpersonal problems and adjustment difficulties
• encouragement and support to increase levels of exercise (Cormie et al. 2018; Hayes et al. 2019).


For additional information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.
2.4.2 Communication with patients, carers and families

The general practitioner is responsible for:

- providing patients with information that clearly describes to whom they are being referred, the reason for referral and the expected timeframes for appointments
- requesting that patients notify them if the specialist has not been in contact within the expected timeframe
- considering referral options for patients living rurally or remotely
- supporting the patient while waiting for the specialist appointment (Cancer Council nurses are available to act as a point of information and reassurance during the anxious period of awaiting further diagnostic information; patients can contact 13 11 20 nationally to speak to a cancer nurse).

More information

Refer to Principle 6 ‘Communication’ for communication skills training programs and resources.
Step 3: Diagnosis, staging and treatment planning

Step 3 outlines the process for confirming the diagnosis and stage of melanoma and for planning subsequent treatment. The guiding principle is that interaction between appropriate multidisciplinary team members should determine the treatment plan.

3.1 Specialist diagnostic work-up

All patients should have a complete skin check.

Unlike other cancers, most tests to confirm a melanoma diagnosis occur in the primary care setting before specialist referral.

Specialist management may include:

- complete excision (in rare instances where a punch, shave or incisional biopsy was performed pre-referral) or re-excision with recommended margins
- imaging (in some circumstances).


3.1.1 Genetic testing (family risk)

In some cases certain pathological subtypes of cancer or tumour tests (immunohistochemistry or tumour genetic tests) may suggest an underlying inherited cancer predisposition.

Anyone diagnosed with cancer should have a detailed personal and family cancer history taken. Consult relevant guidelines <https://www.eviq.org.au/cancer-genetics/referral-guidelines> to determine if referral to a familial cancer service is appropriate.

A familial cancer service assessment can determine if genetic testing is appropriate. Genetic testing is likely to be offered when there is at least a 10 per cent chance of finding a causative ‘gene error’ (pathogenic gene variant; previously called a mutation). Usually testing begins with a variant search in a person who has had cancer (a diagnostic genetic test). If a pathogenic gene variant is identified, variant-specific testing is available to relatives to see if they have or have not inherited the familial gene variant (predictive genetic testing).

Medicare funds some genetic tests via a Medicare Benefits Schedule (MBS) item number but most are not. Depending on the personal and family history, the relevant state health system may fund public sector genetic testing.

Pre-test counselling and informed consent is required before any genetic testing. In some states the treating team can offer ‘mainstream’ diagnostic genetic testing, after which referral is made to a familial cancer service if a pathogenic gene variant is identified. The familial cancer service can provide risk management advice, facilitate family risk notification and arrange predictive genetic testing for the family. The familial cancer service will be relevant to each state and jurisdiction.
Relevant to melanoma, a small percentage (1–2 per cent) of melanomas are due to heritable variations in the CDKN2A and CDK4 genes. Patients that may be appropriate for referral are those with:

- more than one first-degree relative with melanoma (these patients should be referred to a dermatologist for clinical risk assessment)
- three or more relatives with melanoma and/or pancreatic cancer (these patients should be referred to a familial cancer service and undergo a genetic risk assessment) (RACGP 2019).


### 3.2 Staging

Staging is a critical element in treatment planning following surgical excision and should be clearly documented in the patient’s medical record.

Initial melanoma staging occurs with the complete excision of the primary lesion. Most melanomas (thickness < 0.8 mm with adequate margins) do not require further investigation.

Sentinel lymph node biopsy should be considered for patients with melanoma greater than 1 mm thickness and for patients with melanoma greater than 0.75 mm and other high-risk features such as ulceration, to provide optimal staging and prognostic information. If metastatic melanoma is detected, management of the regional lymph nodes region should be discussed. The options are observation with clinical and ultrasound review or completion lymph node dissection (CLND). CLND does not offer any survival benefit over close observation. A subset of patients who have metastatic melanoma detected in the sentinel nodes are likely to be referred to a medical oncologist to discuss the role of adjuvant systemic therapy. Sentinel node biopsy should be performed by a surgeon experienced in the procedure.

Node negative melanoma does not require imaging staging investigations.

If a patient has a positive sentinel lymph node biopsy or has had a primary melanoma and has palpable regional lymph nodes, further staging imaging and referral to a surgeon is required. Images are likely to be a CT scan or a PET-CT scan.

Evidence to suggest metastatic disease, where there has been a previous primary melanoma, or at the time of the diagnosis of a primary melanoma, specialist referral for further investigation may be required.

**More information**

3.2.1 Timeframe for completing investigations
Staging investigations should be completed within two weeks of the specialist’s assessment.

3.3 Performance status
Patient performance status is a central factor in melanoma care and should be clearly documented in the patient’s medical record.

Performance status should be measured and recorded using an established scale such as the Karnofsky scale or the Eastern Cooperative Oncology Group (ECOG) scale.

3.4 Treatment planning
Patients with advanced stage primary melanoma, lymph node involvement or melanoma in unusual sites (e.g. mucosal and disseminated melanoma) are best managed by multidisciplinary teams in a specialist or melanoma facility (Cancer Council Australia Melanoma Guidelines Working Party 2019).

3.4.1 Key considerations beyond treatment recommendations
A number of factors should be considered at this stage:
- the patient’s overall condition, life expectancy, personal preferences and decision-making capacity
- discussing the multidisciplinary team approach to care with the patient
- appropriate and timely referral to an MDM
- pregnancy and fertility
- support with travel and accommodation
- teleconferencing or videoconferencing as required.

3.4.2 Timing for multidisciplinary team planning
The multidisciplinary team should meet to discuss patients with unusual pathology, any patient where treatment may be unclear, and all patients with stage III and IV disease, within four weeks of the initial diagnosis. The level of discussion may vary, depending on the patient’s clinical and supportive care factors. Some patients with non-complex melanoma may not be discussed by a multidisciplinary team; instead the team may have treatment plan protocols that will be applied if the patient’s case (melanoma) meets the criteria. If patients are not discussed at an MDM, they should at least be named on the agenda for noting. The proposed treatment must be recorded in the patient’s medical record and should be recorded in an MDM database where one exists.

Teams may agree on standard treatment protocols for non-complex care, facilitating patient review (by exception) and associated data capture.

Results of all relevant tests and access to images should be available for the MDM. Information about the patient’s concerns, preferences and social and cultural circumstances should also be available.
3.4.3 Responsibilities of the multidisciplinary team

The multidisciplinary team requires administrative support in developing the agenda for the meeting, for collating patient information and to ensure appropriate expertise around the table to create an effective treatment plan for the patient. The MDM has a chair and multiple lead clinicians. Each patient case will be presented by a lead clinician (usually someone who has seen the patient before the MDM). In public hospital settings, the registrar or clinical fellow may take this role. A member of the team records the outcomes of the discussion and treatment plan in the patient history and ensures these details are communicated to the patient's general practitioner. The team should consider the patient’s values, beliefs and cultural needs as appropriate to ensure the treatment plan is in line with these.

3.4.4 Members of the multidisciplinary team for melanoma

The multidisciplinary team should be composed of the core disciplines that are integral to providing good care. Team membership should reflect both clinical and supportive care aspects of care. Pathology and radiology expertise are essential.

See Appendix E for a list of team members who may be included in the multidisciplinary team for melanoma.

Core members of the multidisciplinary team are expected to attend most MDMs either in person or remotely via virtual mechanisms. Additional expertise or specialist services may be required for some patients. An Aboriginal and Torres Strait Islander cultural expert should be considered for all patients who identify as Aboriginal or Torres Strait Islander.

3.4.5 Responsibilities of individual team members

The general practitioner who made the referral is responsible for the patient until care is passed to another practitioner who is directly involved in planning the patient’s care.

The general practitioner may play a number of roles in all stages of the melanoma pathway including diagnosis, referral, treatment, shared follow-up care, post-treatment surveillance, coordination and continuity of care, as well as managing existing health issues and providing information and support to the patient, their family and carer.

A nominated contact person from the multidisciplinary team may be assigned responsibility for coordinating care in this phase. Care coordinators are responsible for ensuring there is continuity throughout the care process and coordination of all necessary care for a particular phase (COSA 2015). The care coordinator may change over the course of the pathway.

The lead clinician is responsible for overseeing the activity of the team and for implementing treatment within the multidisciplinary setting.

3.5 Research and clinical trials

Patients should be encouraged to participate in research or clinical trials where available and appropriate.

For more information visit the Cancer Australia website <www.australiancancertrials.gov.au>.
3.6 Fertility, support and communication

3.6.1 Fertility preservation and contraception

Cancer and cancer treatment may cause fertility problems. This will depend on the age of the patient, the type of cancer and the treatment received. Infertility can range from difficulty having a child to the inability to have a child. Infertility after treatment may be temporary, lasting months to years, or permanent (AYA Cancer Fertility Preservation Guidance Working Group 2014).

Patients need to be advised about and potentially referred for discussion about fertility preservation before starting treatment and need advice about contraception before, during and after treatment. Patients and their family should be aware of the ongoing costs involved in optimising fertility. Fertility management may apply in both men and women. Fertility preservation options are different for men and women and the need for ongoing contraception applies to both men and women.

The potential for impaired fertility should be discussed and reinforced at different time points as appropriate throughout the diagnosis, treatment, surveillance and survivorship phases of care. These ongoing discussions will enable the patient and, if applicable, the family to make informed decisions. All discussions should be documented in the patient’s medical record.

More information


3.6.2 Supportive care

See validated screening tools mentioned in Principle 4 ‘Supportive care’.

A number of specific challenges and needs may arise for patients at this time; however, not all melanoma patients will need this level of support:

- assistance for dealing with psychological and emotional distress while adjusting to the diagnosis; treatment phobias; existential concerns; stress; difficulties making treatment decisions; anxiety or depression or both; psychosexual issues such as potential loss of fertility and premature menopause; history of sexual abuse; and interpersonal problems
- management of physical symptoms such as pain and fatigue (Australian Adult Cancer Pain Management Guideline Working Party 2019)
- malnutrition or undernutrition, identified using a validated nutrition screening tool such as the MST (note that many patients with a high BMI [obese patients] may also be malnourished [WHO 2018])
- support for families or carers who are distressed with the patient’s melanoma diagnosis
- support for families/relatives who may be distressed after learning of a genetically linked melanoma diagnosis
- specific spiritual needs that may benefit from the involvement of pastoral/spiritual care.

Additionally, palliative care may be required at this stage.

For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.
3.6.3 Communication with patients, carers and families

In discussion with the patient, the lead clinician should undertake the following:

- establish if the patient has a regular or preferred general practitioner and if the patient does not have one, then encourage them to find one
- provide written information appropriate to the health literacy of the patient about the diagnosis and treatment and sun protection behaviours to the patient and carer and refer the patient to the Guide to best cancer care (consumer optimal care pathway) for melanoma, as well as to relevant websites and support groups as appropriate
- provide a treatment care plan including contact details for the treating team and information on when to call the hospital
- discuss a timeframe for diagnosis and treatment with the patient and carer
- discuss the benefits of multidisciplinary care and gain the patient’s consent before presenting their case at an MDM
- provide brief advice and refer to Quitline (13 7848) for behavioural intervention if the patient currently smokes (or has recently quit), and prescribe smoking cessation pharmacotherapy, if clinically appropriate
- recommend an ‘integrated approach’ throughout treatment regarding nutrition, exercise and minimal or no alcohol consumption among other considerations
- communicate the benefits of continued engagement with primary care during treatment for managing comorbid disease, health promotion, care coordination and holistic care
- where appropriate, review fertility needs with the patient and refer for specialist fertility management (including fertility preservation, contraception, management during pregnancy and of future pregnancies)
- be open to and encourage discussion about the diagnosis, prognosis (if the patient wishes to know) and survivorship and palliative care while clarifying the patient’s preferences and needs, personal and cultural beliefs and expectations, and their ability to comprehend the communication
- encourage the patient to participate in advance care planning including considering appointing one or more substitute decision-makers and completing an advance care directive to clearly document their treatment preferences. Each state and territory has different terminology and legislation surrounding advance care directives and substitute decision-makers.

3.6.4 Communication with the general practitioner

The lead clinician has these communication responsibilities:

- involving the general practitioner from the point of diagnosis
- ensuring regular and timely (within two weeks of the decision about management) communication with the general practitioner about the diagnosis, treatment plan and recommendations from MDMs and inviting them to participate in MDMs (consider using virtual mechanisms)
- supporting the role of general practice both during and after treatment
- discussing shared or team care arrangements with general practitioners or regional melanoma specialists, or both, together with the patient.

More information

Refer to Principle 6 ‘Communication’ for communication skills training programs and resources.
Step 4: Treatment

Step 4 describes the optimal treatments for melanoma, the training and experience required of the treating clinicians and the health service characteristics required for optimal cancer care.

All health services must have clinical governance systems that meet the following integral requirements:

- identifying safety and quality measures
- monitoring and reporting on performance and outcomes
- identifying areas for improvement in safety and quality (ACSQHC 2020).

Step 4 outlines the treatment options for melanoma. For detailed clinical information on treatment options refer to these resources:


4.1 Treatment intent

The intent of treatment can be defined as one of the following:

- curative
- loco-regional control
- anti-cancer therapy to improve quality of life and/or longevity without expectation of cure
- symptom palliation.

The treatment intent should be established in a multidisciplinary setting, documented in the patient’s medical record and conveyed to the patient and carer as appropriate.

The potential benefits need to be balanced against the morbidity and risks of treatment.

The lead clinician should discuss the advantages and disadvantages of each treatment and associated potential side effects with the patient and their carer or family before treatment consent is obtained and begins so the patient can make an informed decision. Supportive care services should also be considered during this decision-making process. Patients should be asked about their use of (current or intended) complementary therapies (see Appendix D).

Timeframes for starting treatment should be informed by evidence-based guidelines where they exist. The treatment team should recognise that shorter timeframes for appropriate consultations and treatment can promote a better experience for patients.

Initiate advance care planning discussions with patients before treatment begins (this could include appointing a substitute decision-maker and completing an advance care directive). Formally involving a palliative care team/service may benefit any patient, so it is important to know and respect each person’s preference (AHMAC 2011).
4.2 Treatment options

4.2.1 Full skin assessment
A full skin assessment should be considered as a preliminary treatment option for assessing the risk of further melanomas, surveillance planning and for detecting synchronous primaries and/or other keratinocytic skin cancers that may require intervention.

4.2.2 Surgery
The definitive treatment of a primary melanoma involves an adequate margin of skin and subcutaneous fat. For a melanoma in situ, this is 5-10 mm. For an invasive melanoma, the margins of 10 mm or 20 mm will be considered depending on its thickness and specific type of melanoma (Cancer Council Australia Melanoma Guidelines Working Party 2019).

Surgery in a primary care or dermatology centre
Surgery under local anaesthetic with direct primary closure for excision biopsy and selected re-excision for in situ and early-stage melanomas can be undertaken in the primary care setting by a dermatologist or a general practitioner with adequate training and experience.

Surgery by a specialist team
Surgery for all other excisions (including sentinel lymph node biopsy and regional lymphadenectomy) should be undertaken by a surgeon with adequate training and experience.

Resection of regional and distant metastatic melanoma may be appropriate in selected cases.

Timeframe for starting treatment
Surgery in a primary care setting should occur within two weeks of the decision that it is necessary.

Training and experience required of the surgeon
Fellow of the Royal Australian College of Surgeons, or equivalent, with adequate training and experience that enables institutional credentialing and agreed scope of practice in melanoma (ACSQHC 2015).

Documented evidence of the surgeon’s training and experience, including their specific (sub-specialty) experience with melanoma and procedures to be undertaken, should be available.

Health service characteristics
To provide safe and quality care for patients having more advanced surgery, health services should have these features:

- critical care support
- 24-hour medical staff availability
- 24-hour operating room access and intensive care unit
- diagnostic imaging
- pathology
- nuclear medicine imaging.
4.2.3 Radiation therapy

Radiation therapy may benefit patients in the following circumstances:

- definitive treatment for in situ melanoma in special circumstances such as, where surgery needs to be avoided for medical reasons, and sites on the body where complete resection would be prohibitively morbid
- adjuvant radiation therapy following surgical resection for invasive melanoma at high risk of recurrence if potentially effective systemic therapy is not available – at primary sites this includes recurrent disease, desmoplastic melanoma specifically with neurotropism and where adequate margins cannot be attained; at regional sites depending on the location, size and number of nodes specifically when extra-nodal extension is present
- palliative treatment for life prolongation (stereotactic radiotherapy for oligometastatic disease) and symptom relief/prevention, particularly for brain and spinal disease.

Timeframe for starting treatment

If not urgent, radiation therapy should begin within four weeks of the MDM. Some patients will require urgent treatment.

Training and experience required of the appropriate specialists

The radiation oncologist should be a Fellow of the Royal Australian and New Zealand College of Radiologists, or equivalent, with adequate training and experience that enables institutional credentialing and agreed scope of practice in melanoma.

The training and experience of the radiation oncologist should be documented.

Health service unit characteristics

To provide safe and quality care for patients having radiation therapy, health services should have these features:

- linear accelerator (LINAC) capable of image-guided radiation therapy (IGRT)
- dedicated CT planning
- access to MRI and PET imaging
- automatic record-verify of all radiation treatments delivered
- a treatment planning system
- trained medical physicists, radiation therapists and nurses with radiation therapy experience
- coordination for combined therapy with systemic therapy, especially where facilities are not co-located
- participation in Australian Clinical Dosimetry Service audits
- an incident management system linked with a quality management system.

4.2.4 Systemic therapy

Patients with stage III melanoma (confined to regional lymph nodes) and all advanced melanoma (stage IV) should be considered for systemic treatment, given their potential for improvement in progression-free survival and overall survival. Options include immunotherapy and targeted therapy.

Systemic therapy should be prescribed and conducted under the supervision of a medical oncologist.
**Timeframes for starting treatment**

If systemic therapy is to be given as adjuvant therapy, this should occur **within 12 weeks** of the definitive surgery.

If systemic therapy is to be given to treat stage IV disease, therapy should begin as soon as clinically relevant (as soon as possible), **ideally within four weeks**.

**Training and experience required of the appropriate specialists**

Medical oncologists must have training and experience of this standard:

- Fellow of the Royal Australian College of Physicians (or equivalent)
- adequate training and experience that enables institutional credentialing and agreed scope of practice within this area (ACSQHC 2015).

Cancer nurses should have accredited training in these areas:

- anti-cancer treatment administration
- specialised nursing care for patients undergoing cancer treatments, including side effects and symptom management
- the handling and disposal of cytotoxic waste (ACSQHC 2020).

Systemic therapy should be prepared by a pharmacist whose background includes this experience:

- adequate training in systemic therapy medication, including dosing calculations according to protocols, formulations and/or preparation.

In a setting where no medical oncologist is locally available (e.g. regional or remote areas), some components of less complex therapies may be delivered by a general practitioner or nurse with training and experience that enables credentialing and agreed scope of practice within this area. This should be in accordance with a detailed treatment plan or agreed protocol, and with communication as agreed with the medical oncologist or as clinically required.

The training and experience of the appropriate specialist should be documented.

**Health service characteristics**

To provide safe and quality care for patients having systemic therapy, health services should have these features:

- a clearly defined path to emergency care and advice after hours
- access to diagnostic pathology including basic haematology and biochemistry, and imaging
- cytotoxic drugs prepared in a pharmacy with appropriate facilities
- occupational health and safety guidelines regarding handling of cytotoxic drugs, including preparation, waste procedures and spill kits (evIQ 2019)
- guidelines and protocols to deliver treatment safely (including dealing with extravasation of drugs)
- coordination for combined therapy with radiation therapy, especially where facilities are not co-located
- appropriate molecular pathology access.
4.2.5 Targeted therapies and immunotherapy

Stage III melanoma

Patients with resected stage IIIB/C/D melanoma should be considered for adjuvant systemic therapy. The prognosis for patients with stage IIIA melanoma is good and adjuvant systemic therapy is not recommended for this sub-group. For patients with a BRAF V600 mutant melanoma, targeted therapy (combination BRAF and MEK inhibitors) or adjuvant immunotherapy (single agent anti PD-1) can be recommended. For patients without a BRAF mutation, adjuvant immunotherapy should be used. Therapy is given for up to a year.

Currently, there is strong evidence for clinically significant improvements in relapse-free survival with the adjuvant use of targeted therapy or anti-PD1 immunotherapy; however, improvements in overall survival from these treatments have not yet been demonstrated. These may emerge with further follow-up. The decision to recommend adjuvant treatment should be taken by a suitably experienced oncologist and consider the health status and preferences of the individual patient.

Unresectable stage III and stage IV melanoma

All patients with unresectable stage III or stage IV melanoma should be considered for systemic therapy. Enrolment into clinical trials is encouraged where possible.

Immunotherapy, with either anti-PD-1 agents (pembrolizumab or nivolumab) alone or with nivolumab in combination with the anti-CTLA-4 agent ipilimumab can be given as the first line of therapy for metastatic melanoma. Combination immunotherapy results in higher response rates and longer progression-free survival but has significantly greater toxicity, necessitating careful patient selection. Immunotherapy should be continued until disease progression, unacceptable toxicity or completion of two years of treatment. Immunotherapy can cause a unique set of side effects, referred to as immune-related adverse events (irAEs). These toxicities result in inflammation occurring in normal tissues and can affect any part of the body. The most common irAEs are rash, itch, thyroid dysfunction, hypophysitis, hepatitis, colitis, arthritis and pneumonitis. Patients with pre-existing autoimmune conditions are at risk of exacerbation of their autoimmune disease. Clinically significant irAEs require interruption of the immunotherapy and, usually, immunosuppressive doses of corticosteroids. As these are a unique set of toxicities very distinct from traditional chemotherapy side effects, practitioners involved in managing these patients should seek expert advice from the patient’s treating unit if toxicity is suspected.

Patients with BRAF V600 mutant melanoma are also candidates for targeted therapy. Combination therapy with both a BRAF and a MEK inhibitor should be used in preference to treatment with single-agent BRAF inhibition. Treatment with targeted therapy should continue until the development of disease progression or intolerable toxicity. There is no randomised data to suggest a superior sequence of treatment (targeted therapy followed by immunotherapy or vice versa) for metastatic BRAF-mutant melanoma.
4.3 Palliative care

For patients who are not responding to treatment or with very advanced disease, early referral to palliative care can improve the quality of life for people with melanoma, and in some cases may be associated with survival benefits (Haines 2011; Temel at al. 2010; Zimmermann et al. 2014). This is particularly true for cancers with poor prognosis.

The lead clinician should ensure patients receive timely and appropriate referral to palliative care services. Referral should be based on need rather than prognosis. Emphasise the value of palliative care in improving symptom management and quality of life to patients and their carers.

The ‘Dying to Talk’ resource may help health professionals when initiating discussions with patients about future care needs (see ‘More information’). Ensure that carers and families receive information, support and guidance about their role in palliative care (Palliative Care Australia 2018).

Patients, with support from their family or carer and treating team, should be encouraged to consider appointing a substitute decision-maker and to complete an advance care directive.

Refer to step 6 for a more detailed description of managing patients with recurrent, residual or metastatic disease.

More information
These online resources are useful:

- Advance Care Planning Australia <www.advancecareplanning.org.au>
- Care Search <www.caresearch.com.au/Caresearch/>
- Dying to Talk <www.dyingtotalk.org.au>
- the Palliative Care resource kit <www.health.gov.au/health-topics/palliative-care>
- Palliative Care Australia (for patients and carers) <www.palliativecare.org.au>.

4.4 Research and clinical trials

The team should support the patient to participate in research or clinical trials where available and appropriate. Many emerging treatments are only available on clinical trials that may require referral to certain trial centres.

For more information visit the Cancer Australia website <www.australiancancertrials.gov.au>.

4.5 Support and communication

4.5.1 Supportive care

See validated screening tools mentioned in Principle 4 ‘Supportive care’.

A number of specific challenges and needs may arise for patients at this time:

- assistance for dealing with emotional and psychological issues, including body image concerns, fatigue, quitting smoking, traumatic experiences, existential anxiety, treatment phobias, anxiety/depression, interpersonal problems and sexuality concerns
- potential isolation from normal support networks, particularly for rural patients who are staying away from home for treatment
- management of physical symptoms such as pain, fatigue, loss of appetite or weight loss
- decline in mobility or functional status as a result of treatment
- assistance with beginning or resuming regular exercise with referral to an exercise physiologist or physiotherapist (COSA 2018; Hayes et al. 2019).
Early involvement of general practitioners may lead to improved cancer survivorship care following acute treatment. General practitioners can address many supportive care needs through good communication and clear guidance from the specialist team (Emery 2014).

Patients, carers and families may have these additional issues and needs:

- financial issues related to loss of income (through reduced capacity to work or loss of work) and additional expenses as a result of illness or treatment
- advance care planning, which may involve appointing a substitute decision-maker and completing an advance care directive
- legal issues (completing a will, care of dependent children) or making an insurance, superannuation or social security claim on the basis of terminal illness or permanent disability.

Cancer Council’s 13 11 20 information and support line can assist with information and referral to local support services.

For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.

4.5.2 Rehabilitation

Rehabilitation may be required at any point of the care pathway. If it is required before treatment, it is referred to as prehabilitation.

All members of the multidisciplinary team have an important role in promoting rehabilitation. Team members may include occupational therapists, speech pathologists, dietitians, social workers, psychologists, physiotherapists, exercise physiologists and rehabilitation specialists.

To maximise the safety and therapeutic effect of exercise for people with melanoma, all team members should recommend that people with melanoma work towards achieving, and then maintaining, recommended levels of exercise and physical activity as per relevant guidelines. Exercise should be prescribed and delivered under the direction of an accredited exercise physiologist or physiotherapist with experience in cancer care (Vardy et al. 2019). The focus of intervention from these health professionals is tailoring evidence-based exercise recommendations to the individual patient’s needs and abilities, with a focus on the patient transitioning to ongoing self-managed exercise.

Other issues that may need to be dealt with include managing melanoma-related fatigue, improving physical endurance, achieving independence in daily tasks, optimising nutritional intake, returning to work and ongoing adjustment to melanoma and its sequels. Referrals to dietitians, psychosocial support, return-to-work programs and community support organisations can help in managing these issues.
4.5.3 Communication with patients, carers and families

The lead or nominated clinician should take responsibility for these tasks:

- discussing treatment options with patients and carers, including the treatment intent and expected outcomes, and providing a written version of the plan and any referrals
- providing patients and carers with information about the possible side effects of treatment, managing symptoms between active treatments, how to access care, self-management strategies and emergency contacts
- encouraging patients to use question prompt lists and audio recordings, and to have a support person present to aid informed decision making
- initiating a discussion about advance care planning and involving carers or family if the patient wishes.

4.5.4 Communication with the general practitioner

The general practitioner plays an important role in coordinating care for patients, including helping to manage side effects and other comorbidities, and offering support when patients have questions or worries. For most patients, simultaneous care provided by their general practitioner is very important.

The lead clinician, in discussion with the patient's general practitioner, should consider these points:

- the general practitioner's role in symptom management, supportive care and referral to local services
- using a chronic disease management plan and mental health care management plan
- how to ensure regular and timely two-way communication about:
  - the treatment plan, including intent and potential side effects
  - supportive and palliative care requirements
  - the patient's prognosis and their understanding of this
  - enrolment in research or clinical trials
  - changes in treatment or medications
  - the presence of an advance care directive or appointment of a substitute decision-maker
  - recommendations from the multidisciplinary team.

More information

Refer to Principle 6 'Communication' for communication skills training programs and resources.
Step 5: Care after initial treatment and recovery

The term ‘cancer survivor’ describes a person living with cancer, from the point of diagnosis until the end of life. Survivorship care in Australia has traditionally been provided to patients who have completed active treatment and are in the post-treatment phase. But there is now a shift to provide survivorship care and services from the point of diagnosis to improve cancer-related outcomes.

Cancer survivors may experience inferior quality of life and cancer-related symptoms for up to five years after their diagnosis (Jefford et al. 2017). Distress, fear of cancer recurrence, fatigue, obesity and sedentary lifestyle are common symptoms reported by cancer survivors (Vardy et al. 2019).

Due to an ageing population and improvements in treatments and supportive care, the number of people surviving melanoma is increasing. International research shows there is an important need to focus on helping melanoma survivors cope with life beyond their acute treatment. Melanoma survivors often face issues that are different from those experienced during active treatment for melanoma and may include a range of issues as well as unmet needs that affect their quality of life (Lisy et al. 2019; Tan et al. 2019).

Physical, emotional and psychological issues include fear of melanoma recurrence, melanoma-related fatigue, pain, distress, anxiety, depression, cognitive changes and sleep issues (Lisy et al. 2019). Late effects may occur months or years later and depend on the type of melanoma treatment. Survivors and their carers may experience impacted relationships and practical issues including difficulties with return to work or study and financial hardship. They may also experience changes to sex and intimacy. Fertility, contraception and pregnancy care after treatment may require specialist input.

The Institute of Medicine, in its report From cancer patient to cancer survivor: Lost in transition, describes the essential components of survivorship care listed in the paragraph above, including interventions and surveillance mechanisms to manage the issues a cancer survivor may face (Hewitt et al. 2006). Access to a range of health professions may be required including physiotherapy, occupational therapy, social work, dietetics, clinical psychology, fertility and palliative care. Coordinating care between all providers is essential to ensure the patient’s needs are met.

Cancer survivors are more likely than the general population to have and/or develop comorbidities (Vijayvergia & Denlinger 2015). Health professionals should support survivors to self-manage their own health needs and to make informed decisions about lifestyle behaviours that promote wellness and improve their quality of life (Australian Cancer Survivorship Centre 2016; Cancer Australia 2017b; NCSI 2015).
5.1 Transitioning from active treatment

The transition from active treatment to post-treatment care is critical to long-term health. In some cases, people will need ongoing, hospital-based care, and in other cases a shared follow-up care arrangement with their general practitioner may be appropriate. This will vary depending on the type and stage of melanoma and needs to be planned.

Shared follow-up care involves the joint participation of specialists and general practitioners in the planned delivery of follow-up and survivorship care. A shared care plan is developed that outlines the responsibilities of members of the care team, the follow-up schedule, triggers for review, plans for rapid access into each setting and agreement regarding format, frequency and triggers for communication.

After completing initial treatment, a designated member of the multidisciplinary team (most commonly nursing or medical staff involved in the patient’s care) should provide the patient with a needs assessment and treatment summary and develop a survivorship care plan in conjunction with the patient. This should include a comprehensive list of issues identified by all members of the multidisciplinary team involved in the patient’s care and by the patient. These documents are key resources for the patient and their healthcare providers and can be used to improve communication and care coordination.

The treatment summary should cover, but is not limited to:

- the diagnostic tests performed and results
- diagnosis including stage, prognostic or severity score
- melanoma characteristics, specifically the thickness and presence of ulceration
- treatment received (types and dates)
- current toxicities (severity, management and expected outcomes)
- interventions and treatment plans from other health providers
- potential long-term and late effects of treatment
- supportive care services provided
- follow-up schedule
- contact information for key healthcare providers.

5.2 Follow-up care

Responsibility for follow-up care should be agreed between the lead clinician, the general practitioner, relevant members of the multidisciplinary team and the patient. This is based on guideline recommendations for post-treatment care, as well as the patient’s current and anticipated physical and emotional needs and preferences.

Evidence comparing shared follow-up care and specialised care indicates equivalence in outcomes including recurrence rate, cancer survival and quality of life (Cancer Research in Primary Care 2016).

Ongoing communication between healthcare providers involved in care and a clear understanding of roles and responsibilities is key to effective survivorship care.
In particular circumstances, other models of post-treatment care can be safely and effectively provided such as nurse-led models of care (Monterosso et al. 2019). Other models of post-treatment care can be provided in these locations or by these health professionals:

- in a shared care setting
- in a general practice setting
- by non-medical staff
- by allied health or nurses
- in a non-face-to-face setting (e.g. by telehealth).

A designated member of the team should document the agreed survivorship care plan. The survivorship care plan should support wellness and have a strong emphasis on healthy lifestyle changes such as a balanced diet, a non-sedentary lifestyle, weight management and a mix of aerobic and resistance exercise (COSA 2018; Hayes et al. 2019).

This survivorship care plan should also cover, but is not limited to:

- what medical follow-up is required (surveillance for melanoma spread, recurrence or secondary and metachronous cancers, screening and assessment for medical and psychosocial effects)
- model of post-treatment care, the health professional providing care and where it will be delivered
- care plans from other health providers to manage the consequences of melanoma and melanoma treatment
- wellbeing, primary and secondary prevention health recommendations that align with chronic disease management principles
- rehabilitation recommendations
- available support services
- a process for rapid re-entry to specialist medical services for suspected recurrence.

Survivors generally need regular follow-up, often for five or more years after melanoma treatment finishes. The survivorship care plan therefore may need to be updated to reflect changes in the patient’s clinical and psychosocial status and needs.

Processes for rapid re-entry to hospital care should be documented and communicated to the patient and relevant stakeholders.

Surveillance after curative treatment for melanoma can be as follows:

- tumours less than 1 mm thick: follow-up for two years unless the patient is at high risk for a second primary melanoma due to high naevus numbers, multiple dysplastic naevi or a history of melanoma in close relatives (patients should be seen four- to six-monthly for two years and then less frequently, according to risk factors, for an indefinite period)
- tumours more than 1 mm thick: follow-up three- to four-monthly for the first two years, six-monthly review to five years, and lifelong yearly review thereafter
- stage III disease: follow-up three- to four-monthly for the first two years, six-monthly for the next two to three years, and then as deemed clinically necessary.
Imaging may be required according to clinical indication and stage of disease.

Once the intense follow-up has finished, there should be a minimum of annual skin surveillance.

Follow-up assessment should include a comprehensive history and examination including examination of the primary site and lymph nodes and potential sites of metastases and a full skin assessment.

Patients should be made aware that skin self-examination is essential.

Preventative information about sun protection should be provided to patients to prevent future skin cancers.

After the removal or local treatment of a primary melanoma, in most circumstances follow-up care can safely and effectively be provided in the general practice setting. For patients who have had treatment for metastatic melanoma, the short-term follow-up should be shared between the specialist and the general practitioner until specialist assessment is no longer considered necessary. It is important that post-treatment care is based on evidence and is consistent with guidelines.

The lead clinician should discuss (and general practitioner reinforce) options for follow-up at the start and end of treatment. It is critical for optimal aftercare that the designated member of the treatment team educates the patient about the symptoms of recurrence.

General practitioners (including nurses) can:

- connect patients to local community services and programs
- manage long-term and late effects
- manage comorbidities
- provide wellbeing information and advice to promote self-management
- screen for cancer and non-cancerous conditions.

More information

Templates and other resources to help with developing treatment summaries and survivorship care plans are available from these organisations:

- Australian Cancer Survivorship Centre
- Cancer Australia – Principles of Cancer Survivorship
- Cancer Council Australia and states and territories
- Clinical Oncology Society of Australia – Model of Survivorship Care
- eviQ – Cancer survivorship: introductory course
- MyCarePlan.org.au
- South Australian Cancer Service – Statewide Survivorship Framework resources
- American Society of Clinical Oncology – guidelines.

5.2.1 Preventing recurrence

Being SunSmart (especially during sun protection times), not smoking, eating a healthy diet, avoiding or limiting alcohol intake, being physically active and maintaining a healthy body weight may help reduce the risk of primary recurrence or a second primary cancer.

Encourage and support all melanoma survivors to reduce modifiable risk factors for recurrence as well as other chronic diseases. Ongoing coordination of care between providers should also deal with any comorbidities, particularly ongoing complex and life-threatening comorbid conditions.
5.3 Research and clinical trials
Support melanoma survivors to participate in research or clinical trials where they are available and appropriate. These might include studies to understand survivors’ issues, to better manage treatment side effects, or to improve models of care and quality of life.

For more information visit the Cancer Australia website <www.australiancancertrials.gov.au>.

5.4 Support and communication
5.4.1 Supportive care
See validated screening tools mentioned in Principle 4 ‘Supportive care’. Additionally, the ‘Cancer Survivors Unmet Needs (CaSun)’ is another validated screening tool that may help health professionals to identify the unmet needs of patients during survivorship.

A number of specific challenges and needs may arise for melanoma survivors:
- upper and lower limb lymphoedema, which may require referral to a trained lymphoedema specialist
- management of physical symptoms such as pain, fatigue, loss of appetite or weight loss
- financial and employment issues (such as loss of income and assistance with returning to work, and the cost of treatment, travel and accommodation)
- appointing a substitute decision-maker and completing an advance care directive
- legal issues such as completing a will.

For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.

5.4.2 Rehabilitation and recovery
Rehabilitation may be required at any point of the care pathway from the pre-treatment phase through to disease-free survival and palliative care (Cormie et al. 2017).

Issues that may need to be dealt with include managing melanoma-related fatigue, coping with cognitive changes, improving physical endurance, achieving independence in daily tasks, returning to study or work and ongoing adjustment to melanoma and its sequels.

Exercise is a safe and effective intervention that improves the physical and emotional health and wellbeing of melanoma patients. Exercise should be embedded as part of standard practice in melanoma care and be viewed as an adjunct therapy that helps counteract the adverse effects of melanoma and its treatment.

Melanoma survivors may find referral to specific cancer rehabilitation, optimisation programs or community-based rehabilitation appropriate and beneficial. Other options include referral to allied health supports through team care arrangements and mental health plans. Some community support organisations (cancer-related non-government, not-for-profit and charities) provide services to cancer survivors.
5.4.3 Communication with patients, carers and families
The lead clinician (themselves or by delegation) should take responsibility for these tasks:

- explaining the model of post-treatment care and the roles of health professionals involved in post-treatment care including the role of general practice
- explaining the treatment summary and follow-up care plan
- discussing the development of a shared follow-up and survivorship care plan where a model of shared follow-up care has been agreed
- discussing how to manage any of the physical, psychological or emotional issues identified
- providing information on the signs and symptoms of recurrent disease
- providing a survivorship care plan with information on secondary prevention and healthy living
- providing contact details of the care team involved
- providing clear information about the role and benefits of palliative care and advance care planning.

5.4.4 Communication with the general practitioner
The lead clinician should ensure regular, timely, two-way communication with the general practitioner about:

- the patient's progress
- the follow-up care plan
- potential late effects
- supportive and palliative care requirements
- any shared care arrangements
- clarification of various roles in patient care
- a process for rapid re-entry to medical services for patients with suspected recurrence or if there are other concerns.

More information
Refer to Principle 6 'Communication' for communication skills training programs and resources.
Step 6: Managing recurrent, residual or metastatic disease

Patients who present with recurrent, residual or metastatic disease should be managed by a multidisciplinary team and offered timely referral to appropriate physical, practical and emotional support.

Step 6 is concerned with managing recurrent or local residual and metastatic disease. The likelihood of recurrence depends on many factors usually related to the type of cancer, the stage of cancer at presentation and the effectiveness of treatment. Some cancers cannot be eradicated even with the best initial treatment. But controlling disease and disease-related symptoms is often possible, depending on the clinical situation.

6.1 Signs and symptoms of metastatic disease

Metastatic disease will be detected most commonly by patients presenting with symptoms and less commonly via routine follow-up. Access to the best available therapies, including clinical trials, as well as treatment overseen by a multidisciplinary team, are crucial to achieving the best outcomes for anyone with metastatic disease.

Signs and symptoms will depend on the type of melanoma initially diagnosed and the location of metastatic disease. They may be discovered by the patient or by surveillance in the post-treatment period. Symptoms can often present as:

- any new or changing skin lesions
- a cutaneous lump
- palpable regional lymph nodes
- a persistent, unexplained, new symptom.

6.2 Managing metastatic disease

Managing metastatic disease is complex and should therefore involve all the appropriate specialties in a multidisciplinary team including palliative care where appropriate. From the time of diagnosis, the team should offer patients appropriate psychosocial care, supportive care, advance care planning and symptom-related interventions as part of their routine care. The approach should be personalised to meet the patient’s individual needs, values and preferences. The full complement of supportive care measures as described throughout the optimal care pathway and in Appendices A, B and C should be offered to assist patients and their families and carers to cope. These measures should be updated as the patient’s circumstances change.

Survivorship and palliative care should be addressed for patients with recurrent melanoma or melanoma that has metastasised. Many people live with advanced melanoma for many months or years. As survival is improving in many patients, survivorship issues should be considered as part of routine care. Health professionals should therefore be ready to change and adapt treatment strategies according to disease status, prior treatment tolerance and toxicities and the patient’s quality of life, in addition to the patient’s priorities and life plans.
6.3 Multidisciplinary team

If there is an indication that a patient’s cancer has returned, care should be provided under the guidance of a treating specialist. Each patient should be evaluated to determine if referral to the original multidisciplinary team is necessary. Often referral back to the original multidisciplinary team will not be necessary unless there are obvious aspects of care involving different therapeutic and supportive care disciplines not otherwise accessible. The multidisciplinary team may include new members such as palliative care specialists.

6.4 Treatment

Treatment will depend on the location, extent of recurrent or residual disease, previous management and the patient’s preferences.

In managing people with advanced melanoma, treatment may include these options:

- surgery
- systemic therapies
- radiation therapy.

The potential goals of treatment should be discussed, respecting the patient’s cultural values. Wherever possible, written information should be provided.

Encourage early referral to clinical trials or accepting an invitation to participate in research.

6.5 Advance care planning

Advance care planning is important for all patients with a cancer diagnosis but especially those with advanced disease. Patients should be encouraged to think and talk about their healthcare values and preferences with family or carers, appoint a substitute decision-maker and consider developing an advance care directive to convey their preferences for future health care in the event they become unable to communicate their wishes (AHMAC 2011).

More information
Refer to section 4.3 ‘More information’ for links to resources.

Refer patients and carers to Advance Care Planning Australia <www.advancecareplanning.org.au> or to the Advance Care Planning National Phone Advisory Service on 1300 208 582.

6.6 Palliative care

In patients who are not responding to treatment or with very advanced disease, early referral to palliative care can improve the quality of life for people with melanoma, and in some cases may be associated with survival benefits (Haines 2011; Temel et al. 2010; Zimmermann et al. 2014). The treatment team should emphasise the value of palliative care in improving symptom management and quality of life to patients and their carers. Refer to section 4.3 for more detailed information.

The lead clinician should ensure timely and appropriate referral to palliative care services. Referral to palliative care services should be based on the patient’s need and potential for benefit, not prognosis.

More information
Refer to the end of section 4.3 ‘Palliative care’ for links to resources.
6.7 Research and clinical trials
The treatment team should support the patient to participate in research and clinical trials where available and appropriate.

For more information visit the Cancer Australia website <www.australiancancertrials.gov.au>.

6.8 Support and communication
6.8.1 Supportive care
See validated screening tools mentioned in Principle 4 ‘Supportive care’.

A number of specific challenges and needs may arise at this time for patients:

- assistance for dealing with emotional and psychological distress resulting from fear of death or dying, existential concerns, anticipatory grief, communicating wishes to loved ones, interpersonal problems and sexuality concerns
- potential isolation from normal support networks, particularly for rural patients who are staying away from home for treatment
- cognitive changes as a result of treatment and disease progression such as altered memory, attention and concentration (a patient may appoint someone to make medical, financial and legal decisions on their behalf – a substitute decision-maker – before and in case they experience cognitive decline)
- management of physical symptoms including pain, fatigue, loss of appetite or weight loss
- upper and lower limb lymphoedema, which may require referral to a trained lymphoedema specialist
- disfigurement and scarring from appearance-altering treatment (and possible need for a prosthetic), which may require referral to a specialist psychologist, psychiatrist or social worker
- decline in mobility or functional status as a result of recurrent disease and treatments (referral to physiotherapy or occupational therapy may be required)
- coping with hair loss and changes in physical appearance (refer to the Look Good, Feel Better program – see ‘Resource list’)
- appointing a substitute decision-maker and completing an advance care directive
- financial issues as a result of disease recurrence such as gaining early access to superannuation and insurance
- legal issues (completing a will, care of dependent children) and making an insurance, superannuation or social security claim on the basis of terminal illness or permanent disability.
6.8.2 Rehabilitation

Rehabilitation may be required at any point of the metastatic care pathway, from preparing for treatment through to palliative care. Issues that may need to be dealt with include managing melanoma-related fatigue, improving physical endurance, achieving independence in daily tasks, returning to work and ongoing adjustment to melanoma and its sequels.

Exercise is a safe and effective intervention that improves the physical and emotional health and wellbeing of melanoma patients. Exercise should be embedded as part of standard practice in cancer care and be viewed as an adjunct therapy that helps counteract the adverse effects of melanoma and its treatment. When exercising outdoors, sun protection should be an important consideration.

6.8.3 Communication with patients, carers and families

The lead clinician should ensure there is adequate discussion with patients and carers about the diagnosis and recommended treatment, including treatment intent and possible outcomes, likely adverse effects and the supportive care options available.

More information

Refer to Principle 6 ‘Communication’ for communication skills training programs and resources.
Step 7: End-of-life care

Step 7 is concerned with maintaining the patient’s quality of life and meeting their health and supportive care needs as they approach the end of life, as well as the needs of their family and carers.

Some patients with advanced melanoma will reach a time when active treatment is no longer appropriate. The team needs to share the principles of a palliative approach to care when making decisions with the patient and their family or carer. End-of-life care is appropriate when the patient’s symptoms are increasing and functional status is declining.

7.1 Multidisciplinary palliative care

If the treatment team does not include a palliative care member, the lead clinician should consider referring the patient to palliative care services, with the general practitioner’s engagement. This may include inpatient palliative unit access (as required).

The multidisciplinary team may consider seeking additional expertise from these professionals:

- clinical psychologist
- clinical nurse specialist or practitioner
- social worker
- palliative medicine specialist
- pain specialist
- pastoral or spiritual carer
- bereavement counsellor
- music therapist
- art therapist
- cultural expert

The team might also recommend that patients access these services:

- home and community-based care
- specialist community palliative care workers
- community nursing.

If the patient does not already have an advance care directive in place, a designated member of the treatment team should encourage them to develop one in collaboration with their family or carer (AHMAC 2011).

It is essential for the treatment team to consider the appropriate place of care, the patient’s preferred place of death and the support needed for the patient, their family and carers.

The treatment team should also ensure that carers and families receive the information, support and guidance about their role according to their needs and wishes (Palliative Care Australia 2018).
More information

The treatment team can refer patients and carers to these resources:

- Palliative Care Australia <www.palliativecare.org.au>
- Advance Care Planning Australia <www.advancecareplanning.org.au> or to Advance Care Planning Australia’s National Advisory Service on 1300 208 582.

7.2 Research and clinical trials

Clinical trials may help improve palliative care and in managing a patient’s symptoms of advanced melanoma (Cancer Council Victoria 2019). The treatment team should support the patient to participate in research and clinical trials where available and appropriate.

For more information visit the Cancer Australia website <www.australiancancertrials.gov.au>. See ‘Resource list’ for additional clinical trial databases.

7.3 Support and communication

7.3.1 Supportive care

See validated screening tools mentioned in Principle 4 ‘Supportive care’.

A number of specific challenges and needs may arise for patients at this time:

- assistance for dealing with emotional and psychological distress from anticipatory grief, fear of death or dying, anxiety/depression and interpersonal problems
- management of physical symptoms including pain, fatigue, loss of appetite, breathlessness and confusion
- decline in mobility or functional status, affecting the patient’s discharge destination (a referral to physiotherapy, exercise physiology, occupational therapy or social work may be needed)
- appointing a substitute decision-maker and completing an advance care directive
- legal issues (completing a will, care of dependent children) and making an insurance, superannuation or social security claim on the basis of terminal illness or permanent disability
- specific support for families where a parent is dying and will leave behind bereaved children or adolescents, creating special family needs
- arranging a funeral.

These services and resources can help:

- referral to 13 11 20 for Cancer Council Australia’s Pro Bono Program for free legal, financial, small business accounting and workplace assistance (subject to a means test)
- *Sad news sorry business* (Queensland Health 2015) for the specific needs of Aboriginal and Torres Strait Islander people.

For more information on supportive care and needs that may arise for different population groups, see Appendices A, B and C.
7.3.2 Communication with patients, carers and families
The lead clinician is responsible for:

- being open to and encouraging discussion with the patient about the expected disease course, considering the patient’s personal and cultural beliefs and expectations
- discussing palliative care options, including inpatient and community-based services as well as dying at home and subsequent arrangements
- providing the patient and carer with the contact details of a palliative care service
- referring the patient to palliative care in the community according to the carer’s wishes.

7.3.3 Communication with the general practitioner
The lead clinician should discuss end-of-life care planning to ensure the patient’s needs and goals are met in the appropriate environment. The patient’s general practitioner should be kept fully informed and involved in major developments in the patient’s illness path.

More information
For support with communication skills and training programs, see these sources:

- Principle 6 ‘Communication’.
Our thanks to the following health professionals, consumer representatives, stakeholders and organisations consulted in developing this optimal care pathway.

**Expert working group (this edition)**
Professor Mark Smithers (Chair), Surgeon, Princess Alexandra Hospital and University of Queensland
Dr Salvatore Berlangieri, Nuclear Medicine Physician, Austin Health
Associate Professor Paul Fishburn, General Practitioner, Norwest Skin Cancer Centre
Mr David Gyorki, Surgeon, Peter MacCallum Cancer Centre
Dr Andrew Haydon, Medical Oncologist, Alfred Health
Dr Donna Milne, Skin and Melanoma Nurse Consultant, Peter MacCallum Cancer Centre
Dr Maggie Moore, Medical Oncologist, Alfred Health
Dr Yan Pan, Dermatologist, Alfred Health and Peter MacCallum Cancer Centre
Associate Professor Sashendra Senth, Radiation Oncologist, Alfred Health
Professor Robert Thomas, Special Advisor on Health, Professorial Fellow, The University of Melbourne
Ms Julia Brancato, Project Coordinator, Optimal Care Pathways, Cancer Council Victoria

**Expert working group (previous edition)**
Professor Mark Smithers, Queensland Melanoma Project; Director – Upper GI & Soft Tissue, Princess Alexandra Hospital, The University of Queensland (Chair)
Dr Sam Berlangieri, Head Clinical PET, Austin Health
Ms Hannah Burell, Skin and Melanoma Nurse Coordinator, Peter MacCallum Cancer Centre
Dr Andrew Haydon, Medical Oncologist, Alfred Health
Associate Professor John Kelly, Dermatologist, Alfred Health
Dr Scott King, Clinical Director Palliative Care Medicine, Cavalry Health Care Bethlehem
Dr Donna Milne, Skin and Melanoma Nurse Coordinator, Peter MacCallum Cancer Centre
Dr Maggie Moore, Medical Oncologist, Alfred Health
Dr Yan Pan, Dermatologist, Alfred Health
Dr Jeremy Ruben, Radiation Oncologist, Alfred Health
Dr Joe Scopelliti, Clinical Psychologist, Alfred Health
Ms Katherine Simons, Program Manager, North East Melbourne Integrated Cancer Service, Department of Health and Human Services
Dr Neville Steer, General Practitioner, Mornington, Tanti Creek General Practice
Professor Robert Thomas, Chief Advisor on Cancer, Department of Health and Human Services
Ms Kathryn Whitfield, Acting Manager Cancer Services, Department of Health and Human Services
Alexandra Viner, Project Manager – Optimal Care Pathways
Medical colleges and peak organisations invited to provide feedback

Advance Care Planning Australia
Allied Health Professions Australia
Australasian Association of Nuclear Medicine Specialists
Australasian Chapter of Palliative Medicine, Royal Australia College of Physicians
Australian and New Zealand Society of Neuroradiology
Australian and New Zealand Society of Palliative Care
Australian Cancer Survivorship Centre
Australian College of Nursing
Australian Medical Association
Australian Society of Medical Imaging and Radiation Therapy
Australian Society of Plastic Surgeons
Cancer Nurses Society of Australia
Clinical Oncology Society of Australia
Interventional Radiology Society of Australasia
Medical Oncology Group of Australia
Melanoma and Skin Cancer Trials
Melanoma Institute Australia
Melanoma Patients Australia
Oncology Social Workers Australia and New Zealand
Royal Australasian College of Physicians
Royal Australasian College of Surgeons
Royal Australian and New Zealand College of Radiologists
Royal Australian College of General Practitioners
Royal College of Pathologists of Australasia
Skin Cancer College Australasia
The Australasian College of Dermatologists
TROG Cancer Research

Governance – project steering committee representation

Alfred Health
Cancer Australia
Cancer Council Victoria, Strategy and Support Division
Cancer Institute New South Wales
Concord Repatriation General Hospital
New South Wales
Consumer representative
Department of Health Victoria, Commissioning and System Improvement Division, Cancer Unit
National Cancer Expert Reference Group
Olivia Newton-John Cancer Wellness and Research Centre
St Vincent’s Hospital Melbourne

Other stakeholders consulted to provide feedback include relevant Cancer Council committees and networks, Integrated Cancer Services, Primary Health Networks and several health services.
Appendix A: Supportive care domains

Supportive care in cancer refers to the following five domains:

- the physical domain, which includes a wide range of physical symptoms that may be acute, relatively short lived or ongoing, requiring continuing interventions or rehabilitation
- the psychological domain, which includes a range of issues related to the patient’s mental health wellbeing and personal relationships
- the social domain, which includes a range of social and practical issues that will affect the patient, carer and family such as the need for emotional support, maintaining social networks and financial concerns
- the information domain, which includes access to information about cancer and its treatment, recovery and survivorship support services and the health system overall
- the spiritual domain, which focuses on the patient’s changing sense of self and challenges to their underlying beliefs and existential concerns (Palliative Care Victoria 2019).

Fitch’s (2000) model of supportive care recognises the variety and level of intervention required at each critical point as well as the need to be specific to the individual patient (Figure A1). The model targets the type and level of intervention required to meet patients’ supportive care needs.

Figure A1: Fitch’s tiered approach to supportive care
Appendix B: Psychological needs

Distress can occur, particularly for patients with deeply indented scars, such as those that occur with skin grafting and/or with disfigurement, especially of the face, head and neck. Providing patients with tailored and accurate information prior to treatment, facilitating patient decision making about appearance altering treatment, and meeting others with similar personal experience may assist some people.

Consider a referral to a psychologist, psychiatrist, pastoral/spiritual care practitioner, social worker, specialist nurse or a relevant community-based program if the patient has these issues:

- displaying emotional cues such as tearfulness, distress that requires specialist intervention, avoidance or withdrawal
- being preoccupied with or dwelling on thoughts about cancer and death
- displaying fears about the treatment process or the changed goals of their treatment
- displaying excessive fears about cancer progression or recurrence
- worrying about loss associated with their daily function, dependence on others and loss of dignity
- becoming isolated from family and friends and withdrawing from company and activities that they previously enjoyed
- feeling hopeless and helpless about the effect that melanoma is having on their life and the disruption to their life plans
- struggling to communicate with family and loved ones about the implications of their melanoma diagnosis and treatment
- experiencing changes in sexual intimacy, libido and function
- struggling with the diagnosis of metastatic or advanced disease
- having difficulties quitting smoking (refer to Quitline on 13 7848) or with other drug and alcohol use
- having difficulties transitioning to palliative care.

Additional considerations that may arise for the multidisciplinary team include:

- support for the carer – encourage referrals to psychosocial support from a social worker, psychologist or general practitioner
- referral to an exercise physiologist or physiotherapist as a therapeutic approach to prevent and manage psychological health
- referral to wellness-after-cancer programs to provide support, information and offer strategies.
Appendix C: Special population groups

The burden of cancer is not evenly spread across Australia. People experiencing socioeconomic disadvantage, Aboriginal and Torres Strait Islander communities, culturally diverse communities, people living with a disability, people with chronic mental health or psychiatric concerns and those who live in regional and rural areas of Australia have poorer cancer outcomes.

Aboriginal and Torres Strait Islander people

Cancer is the third leading cause of burden of disease for Aboriginal and Torres Strait Islander people. While Australia’s cancer survival rates are among the best in the world, Aboriginal and Torres Strait Islander people continue to experience a different pattern of cancer incidence and significant disparities in cancer outcomes compared with non-Indigenous Australians.

The most common form of melanoma in this group occurs on the palms of the hands, soles of the feet and in nailbeds, so called acral lentiginous melanoma. It is often diagnosed late and as such has a poorer prognosis.

For Aboriginal and Torres Strait Islander people, health and connection to land, culture, community and identity are intrinsically linked. Health encompasses a whole-of-life view and includes a cyclical concept of life–death–life.

The distinct epidemiology of cancer among Aboriginal and Torres Strait Islander people, and unique connection to culture, highlight the need for a specific optimal care pathway for Aboriginal and Torres Strait Islander people with cancer. Ensuring this pathway is culturally safe and supportive is vital to tackling the disparities for Aboriginal and Torres Strait Islander people.

Published in 2018, the Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer provides guidance to health practitioners and service planners on optimal care for Aboriginal and Torres Strait Islander people with cancer across the cancer continuum.

In addition to the key principles underpinning cancer-specific pathways, these are the key concepts that are fundamental to Aboriginal and Torres Strait Islander health:

- providing a holistic approach to health and wellbeing
- providing a culturally appropriate and culturally safe service
- acknowledging the diversity of Aboriginal and Torres Strait Islander peoples
- understanding the social determinants and cultural determinants of health (Cancer Australia 2015).

Culturally diverse communities

For people from culturally diverse backgrounds in Australia, a cancer diagnosis can come with additional complexities, particularly when English proficiency is poor. In many languages there is not a direct translation of the word ‘cancer’, which can make communicating vital information difficult. Perceptions of cancer and related issues can differ greatly in people from culturally diverse backgrounds and this can affect their understanding and decision making after a cancer diagnosis. In addition to different cultural beliefs, when English language is limited there is potential for miscommunication of important information and advice, which can lead to increased stress and anxiety for patients.

A professionally trained interpreter (not a family member or friend) should be made available when communicating with people with limited English proficiency. Navigation of the Australian healthcare system can pose problems for those with a non-Anglo culture, and members of the treatment teams should pay particular attention to supporting these patients.

The Australian Cancer Survivorship Centre has developed a glossary of more than 700 cancer terms in nine different languages. The multilingual glossary has been designed as a resource for professional translators, interpreters and bilingual health professionals working in the cancer field. The glossary is a unique tool that enables language professionals with access to accurate, consistent and culturally appropriate terminology.

Visit the Peter Mac website <www.petermac.org/multilingualglossary> to see the glossary.

People with disabilities

Disability, which can be physical, intellectual or psychological, may have existed before the cancer diagnosis or may be new in onset (occurring due to the cancer treatment or incidentally). Adjusting to life with a disability adds another challenge to cancer care and survivorship.

Several barriers prevent people with disabilities from accessing timely and effective health care (AIHW 2017):

- physical limitations
- competing health needs
- the trauma of undergoing invasive procedures
- potential barriers associated with obtaining informed consent
- failure to provide assistance with communication
- lack of information
- discriminatory attitudes among healthcare staff.

In caring for people with disabilities and a cancer diagnosis, the Australian Institute of Health and Welfare disability flag should be used at the point of admittance to correctly identify and meet the additional requirements of a person with disability. Facilities should actively consider access requirements, and health practitioners should make reasonable adjustments where required.

Patients aged between seven and 65 years who have a permanent or significant disability may be eligible for support or funding through the National Disability Insurance Scheme (National Disability Insurance Agency 2018). More information can be found on the NDIS website <www.ndis.gov.au>.
Patients aged 65 years or older (50 years or older for Aboriginal or Torres Strait Islander people) may be eligible for subsidised support and services through aged care services. An application to determine eligibility can be completed online over the phone. More information can be found at the My Aged Care website <www.myagedcare.gov.au>.

**More information**
‘Talking End of Life’ is a resource that shows how to teach people with intellectual disability about end of life. It is designed for disability support workers but is also helpful for others including families, health professionals and educators.


**Older people with cancer**

Planning and delivering appropriate cancer care for older people can present a number of challenges. This could also be true for frail people or those experiencing comorbidities. Effective communication between oncology and geriatrics departments will help facilitate best practice care, which takes into account physiological age, complex comorbidities, risk of adverse events and drug interactions, as well as the implications of cognitive impairment on suitability of treatment and consent (Steer et al. 2009).

At a national interdisciplinary workshop convened by the Clinical Oncology Society of Australia, it was recommended that people over the age of 70 undergo some form of geriatric assessment, in line with international guidelines (COSA 2013; paliAGED 2018). Screening tools can be used to identify those patients in need of a comprehensive geriatric assessment (Decoster et al. 2015). This assessment can be used to help determine life expectancy and treatment tolerance and guide appropriate referral for multidisciplinary intervention that may improve outcomes (Wildiers et al. 2014).

Frailty is not captured through traditional measures of performance status (e.g. ECOG) and includes assessment in the domains of:

- function
- comorbidity
- presence of geriatric syndromes
- nutrition
- polypharmacy
- cognition
- emotional status
- social supports.
Adolescents and young adults

In recent years, adolescent and young adult oncology has emerged as a distinct field due to lack of progress in survival and quality-of-life outcomes (Ferrari et al. 2010; Smith et al. 2013). The significant developmental change that occurs during this life stage complicates a diagnosis of cancer, often leading to unique physical, social and emotional effects for young people at the time of diagnosis and throughout the cancer journey (Smith et al. 2012).

In caring for young people with cancer, akin to the comorbidities that require specific care in the older cancer population, the treatment team needs to pay careful attention to promoting normal development (COSA 2014). This requires personalised assessments and management involving a multidisciplinary, disease-specific, developmentally targeted approach that adheres to the following principles:

- understanding the developmental stages of adolescence and supporting normal adolescent health and development alongside cancer management
- understanding and supporting the rights of young people
- communication skills and information delivery that are appropriate to the young person
- meeting the needs of all involved, including the young person, their carers and their family
- working with educational institutions and workplaces
- considering survivorship and palliative care needs.

An oncology team caring for an adolescent or young adult with cancer should be able to demonstrate these specific areas of expertise:

- be able to ensure access to expert adolescent and young adult health providers who have knowledge specific to the biomedical and psychosocial needs of the population
- understand the biology and current management of the disease in the adolescent and young adult age group
- consider participating in research and clinical trials for each patient
- engage in proactive discussion and management of fertility preservation, late effects of treatment, ongoing need for contraception, and psychosocial and psychosexual needs
- provide treatment in an environment that is friendly to adolescents and young adults.
People experiencing socioeconomic disadvantage

In general, people from lower socioeconomic groups are at greater risk of poor health, have higher rates of illness, disability and death, and live shorter lives than those from higher socioeconomic groups (AIHW 2016). People experiencing socioeconomic disadvantage are less likely to participate in screening programs, more likely to be obese, less likely to exercise and much more likely to smoke, which are all risk factors for cancer. In 2010–2014 age-standardised cancer incidence rates were higher in the lowest socioeconomic areas compared with the highest socioeconomic areas for all cancers combined (Cancer Australia 2019b).

Socioeconomic status and low health literacy are closely correlated. Therefore, effective communication with patients and carers is particularly important given the prevalence of low health literacy in Australia (estimated at 60 per cent of Australian adults) (ACSQHC 2014).

Consideration should be taken for cancer patients experiencing socioeconomic disadvantage to reduce their risk of being underserved for health care.

People with chronic mental health or psychiatric concerns

A diagnosis of cancer may present additional challenges to people who have pre-existing chronic mental health or psychiatric concerns, resulting in exacerbation of their mental health symptoms. This may include heightened anxiety, worsening depression or thoughts of self-harm.

As poor adjustment and coping can affect treatment decisions, people who are known to have a mental health diagnosis need psychosocial assessment in the oncology setting to formulate a plan for ongoing support throughout treatment.

Psychosocial support can assist with challenges in communicating with health professionals, enhance understanding of the treatment journey, ensure capacity for consent to treatment options and improve compliance with treatment requests. A referral for psychosocial support from a health professional to the psycho-oncology team can ensure these patients are provided with targeted interventions or referrals to community-based services that may mitigate problems associated with the impacts of social isolation that frequently accompany chronic mental ill-health.

Many patients with chronic mental health problems may be well known to external service providers. Psycho-oncology health professionals can form meaningful partnerships with existing service providers to optimise patient care throughout treatment and beyond.

Drug use disorders fall within the area of mental health conditions. People who are opiate dependent may have specific and individual requirements regarding pain management and their own preference for type of opiate prescribed or used.
Sexually and gender diverse groups

People who identify as sexually or gender diverse may have unique needs following a cancer diagnosis. Sexually or gender diverse identities include (but are not limited to) people who identify as lesbian, gay, bisexual or transgender, collectively ‘LGBT’. There is no universally agreed upon initialism to describe this community, with other terms such as queer/questioning (Q), intersex (I), asexual (A) and pansexual (P) often included, as well as a plus symbol (+) indicating inclusivity of other identities not explicitly mentioned.

Sexual orientation and gender identity are relevant across the entire spectrum of cancer care, from prevention to survivorship and end-of-life care. LGBT people are less likely to participate in cancer screening, and some segments of the LGBT community exhibit elevated rates of specific cancer risk factors – for example, higher rates of smoking and alcohol use. Regarding treatment, there may be unique factors relevant to LGBT people that may affect decision making. Additionally, the LGBT population experiences higher rates of anxiety, depression and stressful life circumstances, and may be at risk of inferior psychosocial outcomes following a cancer diagnosis. LGBT people are also more likely to be estranged from their families of origin, and for older people, less likely to have adult children who may provide support and care.

Barriers to care for LGBT people include past negative interactions with healthcare systems, experiences or fear of discrimination and harassment in healthcare settings, assumptions of cisgender/heterosexual identity, lack of recognition or exclusion of same-sex partners from care, and a lack of relevant supportive care and information resources.

To provide safe and appropriate care for LGBT people with cancer, healthcare providers should:

• display environmental cues to show an inclusive and safe setting for LGBT patients
• avoid assumptions about the sexual orientation or gender identity of patients and their partners
• facilitate positive disclosure of sexual orientation or gender identity
• include same-sex/gender partners and families of choice in care
• be aware of relevant supportive care and information resources
• provide non-judgemental, patient-centred care.
Appendix D: Complementary therapies

Complementary therapies may be used together with conventional medical treatments to support and enhance quality of life and wellbeing. They do not aim to cure the patient’s cancer. Instead, they are used to help control symptoms such as pain and fatigue (Cancer Council Australia 2019).

The lead clinician or health professional involved in the patient’s care should discuss the patient’s use (or intended use) of complementary therapies not prescribed by the multidisciplinary team to assess safety and efficacy and to identify any potential toxicity or drug interactions.

The lead clinician should seek a comprehensive list of all complementary and alternative medicines being taken and explore the patient’s reason for using these therapies and the evidence base. A transparent and honest discussion that is free from judgement should be encouraged.

While some complementary therapies are supported by strong evidence, others are not. For such therapies, the lead clinician should discuss their potential benefits and use them alongside conventional therapies (NHMRC 2014).

If the patient expresses an interest in using complementary therapies, the lead clinician should consider referring patients to health providers within the multidisciplinary team who have expertise in the field of complementary and alternative therapies (e.g. a clinical pharmacist, dietitian or psychologist) to assist them to reach an informed decision. Costs of such approaches should be part of the discussion with the patient and considered in the context of evidence of benefit.

The lead clinician should assure patients who use complementary therapies that they can still access a multidisciplinary team review and encourage full disclosure about therapies being used.

More information

Appendix E: Members of the multidisciplinary team for melanoma

The multidisciplinary team may include the following members:

- care coordinator (as determined by multidisciplinary team members)*
- dermatologist*
- medical oncologist*
- nuclear medicine physician*
- nurse (with appropriate expertise)*
- pathologist*
- radiation oncologist*
- radiologist/imaging specialists*
- surgeon*
- Aboriginal health practitioner, Indigenous liaison officer or remote general practitioner
- clinical trials coordinator
- dietitian
- exercise physiologist
- fertility specialist
- general practitioner
- occupational therapist
- palliative care specialist
- pharmacist
- physiotherapist
- psychiatrist
- psychologist
- social worker
- spiritual/pastoral care.

* Denotes core members. Core members of the multidisciplinary team are expected to attend most multidisciplinary team meetings either in person or remotely.
Resource list

For patients, families and carers

**Advance Care Planning Australia**

Advance Care Planning Australia provides national advance care planning resources for individuals, families, health professional and service providers. Resources include a national advisory service, information resources, a legal forms hub and education modules.

- Telephone: 1300 208 582
- Website <www.advancecareplanning.org.au>

**Australian Cancer Survivorship Centre**

The Australian Cancer Survivorship Centre has developed information resources and events to help people move from initial treatment to post treatment and beyond, including those receiving maintenance treatments. While they do not provide clinical advice, they connect with a range of providers to enable improved care.

- Telephone: (03) 8559 6220
- Website <www.petermac.org/cancersurvivorship>

**Australian Commission on Safety and Quality in Health Care**


**Beyond Blue**

Beyond Blue provides information about depression, anxiety and related disorders, as well as about available treatment and support services.

- Telephone: 1300 22 4636
- Website <www.beyondblue.org.au>

**Cancer Australia**

Cancer Australia provides information for consumers, carers and their families including printed resources and video content.

- Website <www.canceraustralia.gov.au>

**Cancer Council’s Cancer Information and Support Service**

Cancer Council 13 11 20 is a confidential telephone support service available to anyone affected by cancer. This service acts as a gateway to evidence-based documented, practical and emotional support available through Cancer Council services and other community organisations. Calls will be answered by a nurse or other oncology professional who can provide information relevant to a patient’s or carer’s situation. Health professionals can also access this service.

- Telephone: 13 11 20 – Monday to Friday, 9.00am to 5.00pm (some states have extended hours)

**Cancer Council’s Cancer Connect**

Cancer Connect is a free and confidential telephone peer support service that connects someone who has cancer with a specially trained volunteer who has had a similar cancer experience.

A Connect volunteer can listen with understanding and share their experiences and ways of coping. They can provide practical information, emotional support and hope. Many people newly diagnosed with cancer find this one-to-one support very beneficial.

For more information on Cancer Connect call Cancer Council on 13 11 20.
Canteen
Canteen helps adolescents, young adults and parents to cope with cancer in their family. Canteen offers individual support services, peer support services and a youth cancer service, as well as books, resources and useful links.
- Telephone: 1800 835 932 to talk to a health professional about information and support for young people or 1800 226 833 for other enquiries
- Website <www.canteen.org.au/>

Clinical trial information
For a collection of clinical trials available in Australia see the following sources of information:
- Australian clinical trials <www.australianclinicaltrials.gov.au>
- Australian New Zealand Clinical Trials Registry <www.anzctr.org.au>
- ClinicalTrials.gov <www.clinicaltrials.gov>.

CanEAT pathway
A guide to optimal cancer nutrition for people with cancer, carers and health professionals.

Guides to best cancer care
The short guides help patients, carers and families understand the optimal cancer care that should be provided at each step. They include optimal timeframes within which tests or procedures should be completed, prompt lists to support patients to understand what might happen at each step of their cancer journey and to consider what questions to ask, and provide information to help patients and carers communicate with health professionals.
The guides are located on an interactive web portal, with downloadable PDFs available in multiple languages.
- Website <www.cancercareguides.org.au>

Look Good, Feel Better
A free national community service program, run by the Cancer Patients Foundation, dedicated to teaching cancer patients how to manage the appearance-related side effects caused by treatment for any type of cancer.
- Telephone: 1800 650 960
- Website <https://lgfb.org.au>

Melanoma Institute Australia
Primarily a research centre, Melanoma Institute Australia also provides education and patient support resources to people or carers affected by melanoma.
- Telephone: (02) 9911 7200
- Website <https://www.melanoma.org.au/>

Melanoma Patients Australia
Melanoma Patients Australia is a national support and advocacy group for patients, family and friends affected by melanoma.
- Telephone: 1300 884 450
- Website <https://melanomapatients.org.au/>
Quitline
Quitline is a confidential, evidence-based telephone counselling service. Highly trained Quitline counsellors use behaviour change techniques and motivational interviewing over multiple calls to help people plan, make and sustain a quit attempt.
Quitline is a culturally inclusive service for all, and Aboriginal counsellors are also available. Health professionals can refer patients to Quitline online or via fax.
• Telephone: 13 78 48
• Website <www.quit.org.au> or the relevant website in your state or territory.

SunSmart
SunSmart is a skin cancer prevention and early detection program. The program provides skin cancer prevention and early detection education, resources and support for workplaces, schools, early childhood services, health professionals and community members.
The free SunSmart app tells you when sun protection is recommended for your location using forecast information from the Bureau of Meteorology website and live UV data from the Australian Radiation Protection and Nuclear Safety Agency.
• Website: <www.sunsmart.com.au>

Scan Your Skin
A skin cancer risk assessment questionnaire to assist people in assessing their skin cancer risk.
• Website <http://www.scanyourskin.org/risk-prediction-tool/>

For health providers

Australasian Lymphology Association
The Australasian Lymphology Association has a number of resources to help people understand lymphoedema and the treatments available.
• Telephone: 1300 935 332
• Website: www.lymphoedema.org.au

Australian Cancer Survivorship Centre
The Australian Cancer Survivorship Centre provides expertise in survivorship care, information, support and education. Its purpose is to support and enable optimal survivorship care.
• Telephone: (03) 8559 6220
• Website <www.petermac.org/cancersurvivorship>

Australian Commission on Safety and Quality in Health Care
The Australian Commission on Safety and Quality in Health Care has developed a guide for clinicians containing evidence-based strategies to support clinicians to understand and fulfil their responsibilities to cancer patients. This guide is particularly relevant to steps 3 to 6 of the optimal care pathway. The guide is titled NSQHS Standards user guide for medication management in cancer care for clinicians <https://www.safetyandquality.gov.au/publications-and-resources/resource-library/nsqhs-standards-user-guide-medication-management-cancer-care-clinicians>.

Cancer Australia
Information for health providers including guidelines, cancer learnings, cancer guides, reports, resources, videos, posters and pamphlets.
• Website <www.canceraustralia.gov.au>
Cancer Council Australia
Information on prevention, research, treatment and support provided by Australia’s peak independent cancer authority.
• Website <www.cancer.org.au>

CanEAT pathway
A guide to optimal cancer nutrition for people with cancer, carers and health professionals.

eviQ
A clinical information resource providing health professionals with current evidence-based, peer-maintained, best practice cancer treatment protocols and information relevant to the Australian clinical environment.
• Website <www.eviq.org.au>

Melanoma and Skin Cancer Trials
This organisation develops, conducts and publishes research and clinical trials that improve how melanoma and skin cancer is diagnosed and treated.
• Website <https://www.masc.org.au/>

Melanoma Research Victoria
Melanoma Research Victoria provides multiple platforms to facilitate varying research disciplines to better understand all aspects of melanoma.
• Telephone: (03) 8559 6530
• Website <https://melanomaresearchvic.com.au/>

National Health and Medical Research Council
• Website <www.nhmrc.gov.au>
**Advance Care Directive** – voluntary person-led document that focuses on an individual’s values and preferences for future health and medical treatment decisions, preferred outcomes and care. They are completed and signed by a competent person. They are recognised by specific legislation (statutory) or common law (non-statutory). Advance care directives can also appoint the substitute decision-maker(s) who can make decisions about health or personal care on the individual’s behalf if they are no longer able to make decisions themselves. Advance care directives focus on the future health care of a person, not on the management of his or her assets. They come into effect when an individual loses decision-making capacity.

**Advance Care Planning** – the process of planning for future health and personal care, where the person’s values, beliefs and preferences are made known so they can guide decision making at a future time when that person cannot make or communicate their decisions.

**Alternative Therapies** – treatments used in place of conventional medical treatment.

**Care Coordinator** – the health provider nominated by the multidisciplinary team to coordinate patient care. The care coordinator may change over time depending on the patient’s stage in the care pathway and the location and care in which care is being delivered.

**Complementary Therapies** – supportive treatment used in conjunction with conventional medical treatment. These treatments may improve wellbeing and quality of life and help people deal with the side effects of cancer.

**End-of-life Care** – includes physical, spiritual and psychosocial assessment, and care and treatment, delivered by health professionals and ancillary staff. It also includes support of families and carers and care of the patient’s body after their death.

**Immunotherapy** – a type of cancer treatment that helps the body’s immune system to fight cancer. Immunotherapy can boost the immune system to work better against cancer or remove barriers to the immune system attacking the cancer.

**Indicator** – a documentable or measurable piece of information regarding a recommendation in the optimal care pathway.

**Informed Financial Consent** – the provision of cost information to patients, including notification of likely out-of-pocket expenses (gaps), by all relevant service providers, preferably in writing, before admission to hospital or treatment (Commonwealth Department of Health 2017).

**Lead Clinician** – the clinician who is nominated as being responsible for individual patient care. The lead clinician may change over time depending on the stage of the care pathway and where care is being provided.

**Metastatic Disease** – cancer that has spread from the part of the body where it started (the primary site) to other parts of the body.

**Multidisciplinary Care** – an integrated team approach to health care in which medical and allied health providers consider all relevant treatment options and collaboratively develop an individual treatment plan for each patient.

**Multidisciplinary Team** – comprises the core disciplines that are integral to providing good care. The team is flexible in approach, reflects the patient’s clinical and psychosocial needs and has processes to facilitate good communication.

**Multidisciplinary Team Meeting** – a meeting of health professionals from one or more clinical disciplines who together make decisions about recommended treatment of patients.

**Optimal Care Pathway** – the key principles and practices required at each stage of the care pathway to guide the delivery of consistent, safe, high-quality and evidence-based care for all people affected by cancer.
**performance status** – an objective measure of how well a patient can carry out activities of daily life.

**primary care health professional** – in most cases this is a general practitioner but may also include general practice nurses, community nurses, nurse practitioners, allied health professionals, midwives, pharmacists, dentists and Aboriginal health workers.

**spiritual care** – the aspect of humanity that refers to the way individuals seek and express meaning and purpose and the way they experience their connectedness to the moment, to self, to others, to nature, and to the significant or sacred.

**substitute decision-maker** – a person permitted under the law to make decisions on behalf of someone who does not have competence or capacity.

**supportive care** – care and support that aims to improve the quality of life of people living with cancer, cancer survivors and their family and carers and particular forms of care that supplement clinical treatment modalities.

**survivorship** – an individual is considered a cancer survivor from the time of diagnosis, and throughout their life; the term includes individuals receiving initial or maintenance treatment, in recovery or in the post-treatment phase.

**survivorship care plan** – a formal, written document that provides details of a person’s cancer diagnosis and treatment, potential late and long-term effects arising from the cancer and its treatment, recommended follow-up, surveillance, and strategies to remain well.

**targeted therapy** – a medicine that blocks the growth and spread of cancer by interfering with specific molecules.
References


Australian Institute of Health and Welfare (AIHW) 2016, Australia’s health 2016, Australia’s health series no. 15. Cat. no. AUS 199, AIHW, Canberra.


Royal Australian College of General Practitioners (RACGP) 2019, Genomics in general practice, RACGP, East Melbourne.


